

Manipulation of Human Ovarian Function: Physiological Concepts and Clinical Consequences*

BART C. J. M. FAUSER AND ARNE M. VAN HEUSDEN

Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Dijkzigt Academic Hospital and Erasmus University Medical School, Rotterdam, The Netherlands

- I. Introduction
- II. Dynamics of Normal Human Follicle Growth and Selection
 - A. Gonadotropin-independent and -dependent follicle growth
 - B. Intrafollicular endocrine changes
 - C. Are estrogens needed for follicle development?
 - D. *In vivo* regulation of follicle maturation in the monkey
 - E. The FSH threshold and window concept for *in vivo* follicle growth
 1. FSH threshold and follicle recruitment
 2. FSH window and single dominant follicle selection
 3. Dominant follicle development
 - F. Modulation of FSH action
 1. Heterogeneity of FSH
 2. Direct interference with FSH action
 3. Intraovarian interference with FSH action by growth factors
- III. Gonadotropin Induction of Ovulation
 - A. The concept of monofollicle growth in anovulatory patients
 - B. Conditions affecting treatment outcome
 1. Patient-related factors
 2. Hormone preparation-related factors
 3. Other factors involved
 - C. Commonly used step-up dose regimens
 1. Conventional step-up protocol
 2. Low-dose, step-up protocol
 - D. Potential for a step-down dose regimen
- IV. Steroid Contraception and Residual Ovarian Activity
 - A. The concept of follicle growth during partial and transient suppression of circulating FSH
 - B. Ovarian suppression during steroid contraception
 1. Significance of initiation of pill intake and duration of treatment
 2. Comparison of different steroid doses, compounds, and regimens
 3. Pill-free interval and pill omission

- C. Follicle growth dynamics during steroid contraceptive regimens
- D. Alternative strategies for contraceptive development
- V. Conclusions and Future Directions

I. Introduction

IN RECENT years much new information related to regulation of human follicle development has become available. Recent techniques for the investigation of human ovarian tissue include immunocytochemistry (allowing direct visualization of proteins in tissue), or *in situ* hybridization for the *in situ* detection of DNA or RNA. New tools such as pelvic ultrasound have been developed allowing the longitudinal monitoring of follicle growth dynamics in a given patient. In addition, assays of steroids and peptides in serum and follicle fluid, together with *in vitro* cultures of human ovarian cells, have generated additional information regarding endocrine and para-/autocrine factors regulating follicle growth.

New insight in the interplay between systemic and intraovarian factors regulating development and atresia of follicles may have significant implications. Relevant clinical conditions include ovarian ageing as well as chronic anovulation in patients presenting with serum FSH and estradiol (E₂) hormone levels within the normal range, frequently diagnosed as polycystic ovary syndrome (PCOS). More effective and safe protocols for stimulation of ovarian function for infertility therapy may be developed. This involves both gonadotropin induction of ovulation (aiming at single dominant follicle growth in anovulatory patients) and so-called 'controlled' ovarian hyperstimulation for *in vitro* fertilization (IVF) (aiming at interfering with single dominant follicle selection to induce ongoing multiple follicle development in ovulatory women).

Due to ongoing concern regarding the potential for side effects and long-term health hazards, doses of combined estrogen/progestin steroid contraceptive pills have been decreased continuously since their introduction in the 1960s. It has been noticed subsequently that tolerance for omission of pill intake, especially around the pill-free interval, has diminished substantially in women using regimens presently on the market. Modest suppression of pituitary gonadotropin secretion during pill intake and recovery of FSH release during the pill-free week creates a situation resembling the early follicular phase of the normal menstrual cycle and allows for substantial residual ovarian activity.

Address reprint requests to: Prof. Bart C. J. M. Fauser, M.D., Ph.D., Director Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Dijkzigt Academic Hospital and Erasmus University Medical School, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.

*Supported in part by the 'Stichting Voortplantingsgeneeskunde' Rotterdam (SVG), the 'Netherlands Organization for Scientific Research' (NWO), and Erasmus University.

Concepts involved in regulation of follicle growth during gonadotropin induction of ovulation (attempting to enhance fertility) as well as during steroid contraception (aiming at inhibiting fertility) are derived from recent findings regarding regulation of ovarian function under physiological circumstances. Therefore, these three conditions have been selected as the major focus of the present review.

II. Dynamics of Normal Human Follicle Growth and Selection

A. Gonadotropin-independent and -dependent follicle growth

Resting primordial follicles continuously enter the growing pool throughout life (for review see Refs. 1–3). The magnitude of depletion of the primordial follicle pool is dependent on age and is most pronounced during fetal development. Oocytes are detectable in fetal ovaries after 16 weeks of gestational age. The great majority of oocytes are lost after the fifth month of intrauterine life, when a maximum of approximately 7 million germ cells have been reported (3). The presence of growing follicles in fetal ovaries has been substantiated extensively (4). At birth, both ovaries contain approximately 1 million primordial follicles. Reproductive life starts with approximately 0.5 million primordial follicles at menarche. Thereafter, loss of follicles takes place at a fixed rate of around 1000 per month, accelerating beyond the age of 35 (5–8). Studies in the rat model suggest indeed that follicle loss is inversely related to the number of primordial follicles present in the ovaries (9). Once follicles are stimulated to grow, they can either reach full maturation and ovulate or become atretic. Follicles are present in the ovary at different stages of development, and large numbers of follicles of different sizes can be observed at any given point of the menstrual cycle (10). The distribution of developmental stages of follicles entering atresia may vary with age (11). It is generally believed that, especially at an early age, loss of follicles is largely due to atresia of primordial follicles (12). It is unknown as yet which factors regulate initiation of growth of primordial follicle (12, 13) and whether maturing follicles may enter atresia at all developmental stages (14).

When primordial follicles enter the growth phase they enlarge by an increase in size of the oocyte together with granulosa cell proliferation (primary follicle). Transition into the secondary follicle stage involves alignment of stroma around the basal lamina and the development of an independent blood supply. The stroma subsequently differentiates into a theca externa (similar to surrounding stroma cells) and a theca interna layer. Theca interna cells express LH receptors early on (15). Development of an antral cavity (at a follicle size ~100 to 200 μm) divides granulosa cells in cells surrounding the oocyte (cumulus) and cells that border the basement membrane. During early preantral follicle development, FSH receptors also become detectable on granulosa cells (7, 15, 16). The time span between a primary and an early antral follicle in the human is unknown but is proposed to be several months. Subsequent stages from early antral to preovulatory follicles exhibit clear morphological characteristics, and the time interval is assessed to be approximately

3 months (for review see Ref. 12) (Fig. 1). An increase in the number of granulosa cells is critically important for the advancement in developmental stages of the follicle. The time interval required for a given follicle to pass these different developmental stages can therefore also be assessed by calculating the granulosa cell-doubling time (duration of mitotic activity *in vitro*) (17).

Under normal conditions, only about 400 follicles reach the mature preovulatory stage and ovulate in a lifetime. Hence, loss of follicles due to atresia — with apoptosis [*i.e.* programmed cell death (18)] as the underlying cellular mechanism — rather than growth and subsequent ovulation should be considered the normal fate of follicles. The importance of oxidative stress in inducing atresia (19) and gonadotropins and various growth factors ('survival factors') to suppress apoptosis (20, 21) has been emphasized recently. FSH decreases apoptosis in granulosa cells obtained from hypophysectomized rats (22) and prevents apoptotic changes of cultured preovulatory follicles (23).

In the human the process of initiation of follicle growth and subsequent exhaustion of the resting pool of primordial follicles appears to be regulated independently of stimulation by gonadotropins (24). Follicles become dependent on stimulation by FSH only at an advanced developmental stage, as will be discussed later (*Section II.E*). For instance, follicles grow up to the early antral stage in long-term hypophysectomized animals (25, 26). Similar numbers of maturing follicles, as compared with controls, have been found in anencephalic fetuses (27, 28), and exposure of ovaries to high gonadotropin levels has failed to result in accelerated follicle loss (12). It appears in the human that follicle development up to the antral stage continues throughout life until depletion of follicles around menopause, even under conditions in which endogenous gonadotropin release is diminished substantially (5, 29). Such conditions include prepubertal childhood (30–33), pregnancy (34–37), and the use of steroid contraceptives (see *Section IV*). In addition, follicle growth up to the early antral stage has been described in women with absent gonadotropin secretion, either due to hypophysectomy, as discussed by Block (1), or to hypothalamic/pituitary failure (38). However, observations in hypogonadal mice suggest that gonadotropins do play a role in initiation and continuation of follicle growth (39). In the rat model it has been suggested that theca cell differentiation and early preantral follicle growth is dependent on subtle stimulation by LH (40, 41). In addition, assessment of ovarian morphology of term infant monkeys showed a reduced number of primordial and primary follicles and increased follicle atresia after hypophysectomy (42). In conclusion, the question of whether the extent and rate of early follicle growth is dependent on exposure to minute amounts of gonadotropins remains unsolved (43, 44). Improved knowledge regarding mechanisms regulating initiation of primordial follicle growth as well as atresia of early stages of follicle development may shed more light on clinical conditions such as ovarian ageing and premature ovarian failure, as well as the great individual variability in menopausal age.

In contrast to early follicle development, stimulation by FSH is an absolute requirement for development of large antral preovulatory follicles. Duration and magnitude of FSH




FIG. 1. Schematic representation of human ovarian follicle development. Primordial follicles entering the growth phase form primary follicles (class 1). This is followed by gonadotropin-independent (tonic) growth (class 1 to 4), and eventually gonadotropin (Gn)-dependent growth. Note that the overall development from a class 1 to a class 5 follicle takes three cycles [Reproduced with permission from A. Gougeon].

stimulation will determine the number of follicles with augmented aromatase enzyme activity and subsequent E_2 biosynthesis. High FSH levels usually occurring during the luteo-follicular transition give rise to continued growth of a limited number (cohort) of follicles. Subsequent development of this cohort during the follicular phase becomes dependent on continued stimulation by gonadotropins. In contrast to other primate species such as the Booroola sheep (14, 45), in the human only a single follicle from the cohort is selected to gain dominance and ovulate every cycle. Remaining cohort follicles enter atresia due to insufficient support by reduced FSH levels. The only exception to this rule is familial dizygotic twins in which ongoing growth and ovulation of multiple follicles occur (46, 47). A reduced rate of follicle atresia due to altered intrafollicular steroidogenesis independent from gonadotropins has recently been proposed as the underlying cause (48).

B. Intrafollicular endocrine changes

The majority of enzymes involved in the biosynthesis of ovarian steroids belong to the cytochrome P-450 gene family (for review see Refs. 49 and 50). This group of enzymes includes: 1) Cholesterol side-chain cleavage enzymes (P-450SCC), which convert cholesterol to pregnenolone. 2) The

P-450C17 enzyme (involving both 17α -hydroxylase and C17,20-lyase activity) converts both progestins (pregnenolone and progesterone) to androgens [dihydroepiandrosterone and androstenedione (AD), respectively]. 3) The aromatase enzyme complex (P-450A ROM), converts androgens [AD and testosterone (T)] to estrogens (estrone and E_2 , respectively). Moreover, a specific DNA sequence, termed Ad4, has recently been identified as a transcription factor regulating the expression of steroidogenic P450 genes. The expression of Ad4-binding protein (a zinc finger DNA-binding protein also known as steroidogenic factor-1) has been shown to correlate with the immunolocalization of steroidogenic enzymes in the human ovary (51).

Two enzymes that are not members of the P-450 gene family are also important for gonadal steroid synthesis: 3β -hydroxysteroid dehydrogenase, converting Δ^5 -steroids (such as pregnenolone) to Δ^4 -steroids (such as progesterone), and 17 ketosteroid reductase converting AD to T and estrone to E_2 .

The cholesterol side-chain cleavage enzyme represents the major rate-limiting step in steroid hormone synthesis. Moreover, proteins involved in the acquisition of cholesterol (including lipoprotein receptors and enzymes involved in *de novo* cholesterol synthesis) have also been shown to be im-

portant for sufficient steroid biosynthesis (50). Patients have been described with mutations in DNA encoding for a protein involved in cholesterol transport within the cell (so-called steroid acute regulatory protein) (52) or encoding for specific enzymes involved in the steroid synthesis pathway (for review see Ref. 53). The significance of each step for normal steroid biosynthesis and subsequent ovarian function has been clarified by the careful description of underlying gene abnormalities and the phenotype expression in the event that certain steroids are lacking.

In vitro studies using cells isolated from human ovarian follicles have demonstrated convincingly that theca cells are the source of follicular androgens (54, 55) — predominantly AD (56, 57) — whereas granulosa cells only produce E_2 when androgens are added to the culture medium (58–60). In the human ovarian follicle, immunocytochemistry (with the use of antibodies against specific enzymes, allowing direct visualization of the distribution of the enzyme in tissue) as well as Northern blot analysis of RNA has shown the P-450C17 enzyme to be restricted to the theca cell layer (61, 62), consistent with the notion that these cells are the major site of intrafollicular androgen production. mRNA levels for P-450C17 are increased dramatically in preovulatory follicles (63), which correlate well with augmented 17α -hydroxylase activity of human theca cells in culture (64). Small antral follicles were shown to lack P-450AROM mRNA. However, appreciable quantities of mRNA (63, 65, 66) and the aromatase enzyme (62, 67) were observed in dominant follicles in the late follicular phase. These observations are in keeping with the high level of aromatase enzyme activity expressed *in vitro* by granulosa cells obtained from preovulatory follicles (59, 68). In addition, mRNA expression is in good agreement with immunolocalization of the aromatase enzyme (66). Synthesis of the P-450AROM enzyme could also be induced by FSH administration to human granulosa cells in culture (69). When follicles mature, granulosa cells also exhibit elevated mRNA levels for P-450SCC, LH receptor, activin, and inhibin (70).

The theca interna layer of developing follicles responds to LH and synthesizes androgens (71, 72). AD and its immediate metabolite T are transferred from the theca layer to the intrafollicular compartment. For this reason these steroids are present in large quantities in ovarian follicles of all sizes and represent the main steroid produced by early antral follicles (73–75). Atretic follicles of all sizes (between 2 and 13 mm diameter) also contain high androgen levels (57, 76) and low E_2 concentrations (77). Granulosa cells become responsive to FSH only at more advanced stages of development and are capable of converting the theca cell-derived substrate AD to E_2 by induction of the aromatase enzyme. This so-called 'two-gonadotropin, two-cell' concept emphasizes that adequate stimulation of both theca cells by LH and granulosa cells by FSH is required for adequate E_2 biosynthesis, as has been recognized since the 1940s (54, 78–82).

Large (>8 mm diameter) follicles in the mid- and late follicular phase of the menstrual cycle contain appreciable (up to 10,000-fold) higher quantities of E_2 compared with small follicles, as has been shown by numerous authors (60, 75, 76, 83–87). Intrafollicular E_2 concentrations were up to 40,000-fold higher than those in peripheral plasma, and 20-

fold higher concentrations of E_2 have been observed in venous blood draining the ovary containing the dominant follicle as compared with the contralateral side (88, 89). It has been demonstrated in IVF patients that a correlation exists between the E_2 /androgen ratio in follicle fluid and follicular health and fertility potential of oocytes (90). After enucleation of the largest follicle no further differences were found in steroid levels in blood draining both ovaries (91). A correlation between intrafollicular E_2 concentrations and follicle diameter has been substantiated in large dominant follicles (75, 77, 83). All studies show low E_2 levels in relatively small (<10 mm diameter) nondominant follicles (57, 68, 76, 77, 83), and the absence of a correlation between follicle size and E_2 levels in this size range (Fig. 2) was emphasized recently (75). The magnitude of E_2 synthesized by granulosa cells *in vitro* is dependent on the size of the follicle from which cells were obtained, with AD metabolized to E_2 only by granulosa cells from follicles beyond 8–10 mm in diameter (59, 68, 92). Follicle fluid E_2 concentrations are also correlated with the amount of aromatase activity expressed *in vitro* (60). In addition, granulosa cells in culture produce larger quantities of E_2 in response to similar doses of FSH if cells were obtained from larger (>8 mm) follicles (59, 68, 92), suggesting increased sensitivity. Moreover, lower doses of FSH induce similar E_2 production by cultured rat granulosa cells obtained from larger follicles, again indicating that cells obtained from more mature follicles exhibit augmented sensitivity for stimulation by FSH (93). Finally, a distinct relationship was observed between follicle diameter and the number of granulosa cells that was recovered at each size (94).

Collectively, overwhelming *in vivo* and *in vitro* evidence, both in animal models and in the human, suggest that enhanced E_2 biosynthesis is closely linked to preovulatory follicle development and that high estrogen output of the dominant follicle is regulated by FSH-stimulated granulosa cell function. Development of smaller follicles in the early follicular phase, although dependent on FSH, is not associated with increased E_2 production.

C. Are estrogens needed for follicle development?

As discussed above, dominant follicle development in the human is closely associated with increased follicular estrogen biosynthesis. E_2 receptors have been shown to be present in rat granulosa cells, as studied by ligand-binding assays (95). Numerous *in vitro* studies have shown for the rat model that E_2 plays important autocrine roles in stimulating FSH-induced granulosa cell proliferation (76, 96), aromatase enzyme induction (97–99), production of inhibin (100), increase in E_2 and FSH receptors (101), and formation of LH receptors on granulosa cells (102, 103). In addition, E_2 exhibits a paracrine action on adjacent theca cells by inhibiting androgen production (72). Estrogen (diethylstilbestrol) treatment of immature hypophysectomized rats stimulates growth of large numbers of follicles. Human chorionic gonadotropin (hCG) and FSH-induced follicle development could be inhibited by the administration of estradiol antiserum (104), suggesting again autocrine stimulatory roles for endogenous estrogens. Estrogens have also been shown to inhibit apo-




FIG. 2. Intrafollicular steroid concentrations as related to follicle diameter in 281 nondominant follicles punctured during various phases of the menstrual cycle (box and whisker plots; left panel), and 45 dominant follicles punctured during the late-follicular phase (right panel) obtained from 55 regularly cycling volunteers. Please note that follicle size is only associated with intrafollicular E_2 levels when a diameter of 10 mm or more is obtained. P, Progesterone; AD, androstenedione; E_2 , estradiol. [Reproduced with permission from T. van Dessel *et al.*: *Clin Endocrinol (Oxf)* 44:191–198, 1996 (75).]

ptotic changes of ovarian follicles (20). Based on these observations, the concept has arisen that augmented intrafollicular E_2 production is a *conditio sine qua non* for ongoing follicle maturation. In fact, absent induction of aromatase enzyme activity has been widely accepted as the underlying cause of follicle maturation arrest and subsequent anovulation in PCOS (105).

Several lines of evidence, however, gave strong support to the notion that this may not be the case for higher species, including the human. Under normal conditions, augmented E_2 levels may merely be associated with normal follicle de-

velopment. A deficiency of the 17α -hydroxylase enzyme due to a specific gene defect affects both adrenal steroidogenesis and androgen and estrogen production by the ovary. This condition is characterized by hypergonadotropic hypogonadism, with arrest of follicle development at the early antral stage (106). However, normal follicle development could be induced in these patients by FSH treatment for IVF (after GnRH agonist suppression of endogenous gonadotropin release) despite extremely low intrafollicular levels of AD, T, and E_2 . Oocytes could be obtained and fertilized *in vitro* resulting in normal early embryo

development (107, 108). In another patient suffering from a partial P-450C17 (17, 20-lyase step) deficiency, follicle growth could also be achieved after the administration of exogenous FSH despite low intrafollicular E_2 levels (109). Subsequent IVF and cleavage rates were not different from normal. Moreover, two unrelated females have been described recently with mutations in the CYP19 gene (consisting of 10 exons, and localized on chromosome 15, q21.1 region), resulting in the total absence of aromatase enzyme activity (110, 111). Large ovarian cysts have been described in both patients, suggesting that growth of antral follicles can occur in the absence of intraovarian estrogen biosynthesis. Recent experiments in monkeys treated with an aromatase inhibitor between day 8 and 10 of the follicular phase have also excluded the possibility that increased levels of circulating E_2 in the late follicular phase is required to sustain follicle maturation (112).

We have recently participated in a study on safety and pharmacokinetic properties of human recombinant FSH (113, 114) in hypogonadotropic female volunteers. The complete absence of endogenous as well as exogenous LH in these subjects did provide the unique opportunity to study effects of FSH alone on ovarian steroid production and fol-

licle growth (115). Despite a significant increase in serum FSH levels, in the same order of magnitude as the intercycle rise in FSH during the normal menstrual cycle, serum E_2 levels remained low. However, development of multiple preovulatory follicles emerged within 14 days. In a single subject, three large follicles between 13 and 18 mm in diameter were aspirated, and extremely low intrafollicular levels of AD and E_2 were found (Fig. 3) (87). A normal rise in immunoreactive serum inhibin levels in the majority of these women excluded the possibility of granulosa cell abnormalities *per se* (38). A discrepancy between serum E_2 levels and follicle development has also been observed in hypogonadotropic women comparing purified FSH of urinary origin and human menopausal gonadotropin (HMG; 1:1 ratio of LH to FSH activity) (116). When urinary FSH was combined with long-term GnRH agonist comedication suppressing the endogenous release of LH and FSH, similar observations were reported (117). It is of special interest to note that large antral follicles were also observed in the ovaries of two amenorrheic patients described with inactivating mutations of the LH receptor (and consequently low E_2 production) (118, 119). These observations in the human confirm the two-cell, two-gonadotropin concept for adequate E_2 synthesis but also




FIG. 3. Endocrine and sonographic observations in a single patient with isolated gonadotropin deficiency receiving daily intramuscular injections of human recombinant FSH (hrFSH). Serum FSH and LH levels, follicle diameter, and endometrial thickness (as assessed by TVS) are indicated in the *left panel*. Serum estradiol levels and follicle fluid estradiol and androstenedione concentrations (three follicles, 13–18 mm in diameter) from the patient and from regularly cycling controls [both nondominant (3–9 mm) and dominant (13–24 mm) follicles] are depicted in the *right panel*. HCG, Human chorionic gonadotropin. [Reproduced with permission from B. C. Schoot *et al.*: *J Clin Endocrinol Metab* 74:1471–1473, 1992 (87). © The Endocrine Society.]

demonstrate convincingly that increased E_2 production is not mandatory for normal follicle growth up to the preovulatory stage. These observations are fully supported by more recent similar studies in the monkey. Follicular growth and oocyte maturation in LH-deficient macaques did occur with FSH alone (120), and fertilization rates of oocyte obtained from recFSH/GnRH antagonist-treated monkeys were not compromised (121).

It is still uncertain whether estrogen receptors are present on granulosa cells from higher primates, including the human. Stouffer and colleagues were unable to show estrogen receptors on primate granulosa cells by immunocytochemistry (122), whereas androgen receptors could be demonstrated on both theca and granulosa cells (123). However, this technique may not be sensitive enough to detect low levels of receptors, and some investigators have recently described low levels of estrogen receptor mRNA as well as the protein in human granulosa cells from preovulatory follicles (124, 125). Moreover, direct effects have been described of the antiestrogen clomiphene citrate on E_2 synthesis by cultured human granulosa cells (126). As opposed to rats, diethylstilbestrol administration in juvenile primates resulted in decreased numbers of medium sized developing antral follicles (127). In addition, studies in hamsters have suggested that estrogens exert inhibitory effects on follicle function (128).

Collectively, these data suggest that in the human, E_2 is not required for follicle development. It appears that, under normal conditions, augmented E_2 synthesis is merely associated with dominant follicle development, where growth of the follicle is, in fact, driven by other nonsteroidal (growth) factors (see also *Section II.F*). This concept may also bear significance for our thinking regarding underlying causes of anovulation, in particular in polycystic ovaries. Follicles may cease to mature due to defective intraovarian regulatory mechanisms rather than the absence of aromatase enzyme induction *per se* (129).

During the follicular phase of the normal menstrual cycle E_2 is clearly important for other crucial physiological processes such as stimulation of endometrial proliferation, cervical mucus production, and induction of the midcycle LH surge and subsequent ovulation. Whether oocyte maturation in the human requires exposure to estrogens remains unclear at this stage (130–132).

D. In vivo regulation of follicle maturation in the monkey

A series of *in vivo* studies in the monkey has systematically addressed endocrine factors regulating follicle growth (for comprehensive reviews see Refs. 133–137). A significant proportion of these experiments have subsequently been confirmed in the human (see *Section II.E*). Surgical ablation of the dominant follicle in the late follicular phase of the cycle blocked the midcycle gonadotropin surge and ovulation. These observations indicate that no other follicles from the recruited cohort were capable of replacing the dominant follicle, presumably due to atretic changes. New follicle recruitment occurred in response to a rise in endogenous FSH levels, similar to ovarian response after removal of the corpus luteum. The duration until the next ovulation was 12 days, which equals the normal follicular phase of the cycle. There-

fore ovulation was delayed after follicle cauterization and advanced after luteectomy (138). Ovarian response to exogenous gonadotropins (as estimated by rising serum E_2 levels) was equal, regardless of whether gonadotropins were administered in the follicular or midluteal phase of the cycle (139). By repeated cauterization of the dominant follicle, it was also shown that the midcycle gonadotropin surge of the preceding cycle plays no role in follicle recruitment for the subsequent cycle (140).

Dominant follicle selection, and subsequent asymmetrical ovarian estrogen output, occurs around the midfollicular phase (141, 142). The dominant follicle requires continued though reduced support by FSH. In fact, growth of a single dominant follicle could be sustained in GnRH antagonist-treated monkeys by the administration of exogenous FSH in decremental doses (Fig. 4) (143), suggesting enhanced sensitivity for FSH when the dominant follicle matures (see also *Sections II.B* and *II.E.2*). The dominant follicle continued its development despite relatively low late follicular phase FSH concentrations, incapable of stimulating growth of less mature follicles. Subsequent experiments in the monkey model have addressed the significance of FSH for single dominant follicle selection. Early follicular phase administration of E_2 caused a significant reduction in serum FSH and a lengthening of the follicular phase (144). Moreover, administration of antiestrogen antibodies in the early to midfollicular phase gives rise to elevated serum FSH levels, which interferes with single dominant follicle selection resulting in ongoing maturation of additional cohort follicles (145, 146).

The above mentioned experiments show similar responsiveness of the ovary to endocrine changes in either the luteal (147) or the follicular phase and provide *in vivo* evidence for the concept that gonadotropin-responsive follicles are maintained throughout the entire cycle. Follicles can be stimulated to ongoing and gonadotropin-dependent development when the appropriate endocrine signal (*i.e.* elevated serum FSH levels) is operative. Under normal conditions, elevated FSH concentrations are present during the luteo-follicular transition only. Augmented E_2 production by the most mature (dominant) follicle starting around the midfollicular phase causes a subsequent decrease in FSH levels due to negative feedback effects of E_2 on the hypothalamic-pituitary axis. The dominant follicle restricts ongoing maturation of other, less mature follicles from the cohort since FSH levels drop below their threshold for stimulation of gonadotropin-dependent growth. The dominant follicle is spared from the inhibitory influence of reduced FSH stimulation because of increased sensitivity to FSH (see also *Sections II.B* and *II.E.2*).

E. The FSH threshold and window concept for in vivo follicle growth

1. FSH threshold and follicle recruitment. Due to the demise of the corpus luteum and the subsequent decrease in estrogen production (148), FSH levels rise at the end of the luteal phase of the human menstrual cycle (149). This intercycle rise is closely synchronized with ovulation, and FSH levels start to increase 12 days after the preceding LH surge (150). As mentioned previously, initiation of growth of primordial follicles occurs continuously and in a random fashion. Fol-




FIG. 4. Serum hormone levels (mean \pm SEM; solid line) in four GnRH antagonist-treated monkeys during pulsatile infusion of LH and FSH. FSH infusion was reduced by 12.5%/day after a rise in serum estradiol levels, whereas LH input was kept constant. The shaded areas represent control values ($n = 4$). Note that estradiol levels continue to increase despite decreasing FSH serum levels. [Reproduced with permission from A. J. Zeleznik and C. J. Kubik: *Endocrinology* 119:2025–2032, 1986 (143). © The Endocrine Society.]

licle growth will eventually cease and follicles will enter atresia if the appropriate endocrine signal is lacking. Although each follicle may have an equal potential to reach full maturation, only follicles that happen to be at a more advanced stage of development during the intercycle rise in FSH will gain gonadotropin dependence. The concept that FSH concentrations above a certain level, referred to as the 'FSH threshold,' are needed for ovarian stimulation was first introduced by Brown in 1978 (151) and substantiated more recently by Schoemaker and colleagues. The individual variation in FSH serum levels at which follicle growth was initiated could be assessed to be between 5.7 and 12.0 IU/liter with the use of intravenous administration of gonadotropins in PCOS patients (152, 153). Moreover, multifollicular growth was shown to be associated with higher FSH concentrations above the threshold (153) (Fig. 5), using a low-

dose incremental protocol for FSH induction of ovulation. Each growing follicle has a threshold requirement for stimulation by circulating FSH. The threshold level should be surpassed to ensure ongoing preovulatory follicle development. This process of rescue of a cohort of follicles from atresia by FSH stimulation is referred to by most authors as 'recruitment.' The recruited cohort represents a group of follicles at a comparable (but not identical) developmental stage. This group of follicles, by chance, happened to leave the pool of resting follicles around the same period of time several months before. In contrast, other investigators reserve this term for the initiation of growth of primordial follicles (12) (see also *Section II.A*).

Morphological and endocrine studies suggest that healthy early antral follicles less than 4 mm in diameter are present throughout the cycle (89), in keeping with the concept that




FIG. 5. Increase in FSH serum levels from basal to above the assessed threshold (ATV, above threshold dose) related to the number of FSH ampoules infused per day in 16 PCOS patients treated with a low-dose step-up regimen for gonadotropin induction of ovulation. It was proposed that multifollicular development (\blacktriangle) is associated with higher FSH levels above the threshold and more ampoules per day as compared with patients presenting with monofollicle development (\circ). [Reproduced with permission from M. van der Meer *et al.*: *Hum Reprod* 9:1612–1617, 1994 (153).]

follicles are continuously available for stimulation by FSH. At the end of the luteal phase, the largest healthy follicles observed by morphological criteria have been described to be between 2 to 5 mm in diameter (10, 89, 154), and the number of recruitable follicles present is believed to be between 10 and 20 for both ovaries. Granulosa cells obtained from follicles in the late luteal phase are significantly more sensitive to FSH stimulation (as assessed by FSH-induced estrogen production *in vitro*) (154), suggesting that these healthy follicles will be recruited for the next cycle. The largest healthy follicles at the start of the follicular phase of the cycle have been reported to exhibit a diameter between 4 and 8 mm (94, 155), and no morphological differences exist between these follicles. These observations strongly suggest that the dominant follicle is selected at a later stage of the follicular phase of the cycle. Indeed, exogenous HMG administered during different phases of the menstrual cycle is most effective in stimulating follicle recruitment if administered during the late luteal or early follicular phase (156).

Elegant experiments in the human have further substantiated the FSH threshold concept and have generated additional support for the notion that follicles ready to be recruited are present throughout the menstrual cycle. Removal of the dominant follicle in the late follicular phase, or luteectomy in the luteal phase during gynecological surgery, results in new follicle recruitment and subsequent ovulation (157–159). Enucleation of the corpus luteum in 10 women was followed by an immediate and rapid decline of E_2 and progesterone levels. This was followed by rising FSH levels, renewed follicle growth, and ovulation within 16–19 days after enucleation (159). These experimental results are in full

agreement with observations in the monkey model after similar intervention and indicate indeed that suppressed gonadotropin secretion (due to corpus luteum or dominant follicle steroid production) is responsible for inhibition of more advanced follicle maturation. Moreover, these observations are in keeping with the notion that final and gonadotropin-dependent follicle growth preceding ovulation takes approximately 14 days, coinciding with the follicular phase length of the menstrual cycle. If the intercycle rise in serum FSH is shortened by the early to midfollicular phase administration of GnRH antagonist, follicle growth is arrested and new follicle recruitment will follow once medication is withdrawn (160, 161).

2. FSH window and single dominant follicle selection. In follicles less than 10 mm, the aromatase enzyme is poorly expressed (62) and intrafollicular E_2 levels are low (Fig. 3) (57, 75, 162). This also holds true for follicles in the early follicular phase of the menstrual cycle. E_2 production, however, can be stimulated rapidly *in vitro* by adding FSH to the culture medium (59, 68, 92). It cannot be readily explained why E_2 levels remain low despite maximum FSH stimulation in the early follicular phase (163). Intraovarian modification of FSH action may be involved (see Section II.F.3). Under normal conditions, the fate of developing antral follicles is closely associated with their ability to create an estrogen-rich intrafollicular environment, as discussed previously. It may be proposed that the follicle selected to gain dominance is the one that has most rapidly acquired the highest sensitivity for FSH. This may be the follicle that was at the most advanced developmental stage when recruited. Indeed, FSH respon-


siveness of cultured granulosa cells (obtained from follicles at various stages of development) has been shown to be dependent on follicle size, with more pronounced E_2 production by cells obtained from larger follicles (59, 68, 92, 162). Responsiveness to FSH stimulation is also increased in preovulatory follicles (164). In addition, in the late follicular phase, steroidogenic function of granulosa cells from the dominant follicle is also stimulated by LH (165). Finally, observations in the monkey suggest that increased vascularization of individual follicles (resulting in the preferential exposure to circulating factors) may also be instrumental in the selective maturation of preovulatory follicles (166).

Consequently, the FSH threshold for a given follicle is not fixed but is dependent on its developmental stage and therefore changes over time. Indeed, experiments applying GnRH antagonist for 3 consecutive days in the mid- or late follicular phase of the cycle have shown convincingly that the developing follicle becomes more resistant to gonadotropin withdrawal as it becomes more mature (160). Midfollicular administration of GnRH antagonist may induce a transient follicular arrest without triggering new folliculogenesis (167) or complete follicle maturation arrest and new follicle recruitment (161), depending on the magnitude and duration of gonadotropin suppression.


FSH serum levels steadily decrease during the mid- to late follicular phase of the menstrual cycle. The follicle that has gained dominance is less dependent on continued support by high early follicular phase FSH levels. However, circulating FSH levels are suppressed to a concentration below the threshold for remaining follicles from the recruited cohort. These follicles will therefore cease to mature and undergo atresia. Hence, development of the most mature follicle, closely associated with increased E_2 production, secures selection of a single dominant follicle. The FSH 'gate' (168) or 'window' (169, 170) (Fig. 6, upper panel) concept has been introduced to emphasize the significance of a transient elevation of FSH above the threshold. This concept emphasizes the importance of time (*i.e.* duration of elevated FSH levels) rather than dose (magnitude of FSH elevation) for single dominant follicle selection. Previous studies by our own group in 16 female volunteers have characterized follicular phase patterns of FSH serum levels and investigated correlations between decremental FSH levels and dominant follicle development (163) (see also Table 1 and Fig. 7, where the number of volunteers has been extended to 42). This decrease may be due to negative estrogen feedback on the hypothalamic-pituitary axis (168). However, it seems that the initiation of declining serum FSH levels precedes augmented ovarian estrogen output. We have observed a clear association between the magnitude of decrease in endogenous FSH serum levels and the E_2 rise, indicating that the duration of FSH stimulation (duration of serum FSH above the threshold) is a major determinant for ovarian E_2 production (163).

Indeed, a more pronounced but transient elevation of serum FSH concentrations above the threshold in the early follicular phase of the normal menstrual cycle (administration of 450 IU FSH on cycle day 2) did not result in multiple follicle development and enhanced E_2 production during the late follicular phase. In sharp contrast, low doses of FSH administered during the mid- to late follicular phase (starting

Follicular phase of the normal menstrual cycle



Step-down dose regimen for gonadotropin induction of ovulation



7 day pill-free interval during steroid contraceptive medication




FIG. 6. Schematic representation of the intercycle rise in serum FSH levels (FSH threshold/window concept), and follicle growth dynamics (recruitment, selection, and dominance) during the follicular phase of the normal menstrual cycle (upper panel). FSH serum levels during the follicular phase of gonadotropin induction of ovulation using a step-down dose regimen (starting dose of 150 IU/day) are depicted in the middle panel. FSH serum levels and follicle growth during the 7-day pill-free interval following combined steroid contraceptive pills (OAC) are indicated in the lower panel. The FSH threshold is the serum level required for stimulation of ovarian activity. The FSH window represents the number of days when FSH concentrations remain above the threshold. Recruitment represents the transition from gonadotropin-independent to gonadotropin-dependent follicle development (follicles are rescued from their destiny to undergo atresia by the intercycle rise in FSH). Selection refers to the process where a single follicle gains dominance over the remaining follicles from the recruited cohort.

TABLE 1. Endocrine and sonographic characteristics of the follicular phase of the normal menstrual cycle in 42 volunteers[#]

	Median (range)
Cycle day 1	
FSH concentration (IU/liter)	4.0 (0.9–9.2)
E ₂ concentration (pg/ml)	41 (20–129)
Follicle diameter (mm)	6 (4–15)
FSH	
Maximum	
Concentration (IU/liter)	6.6 (4.3–12.5)
Cycle day	5 (1–9)
Minimum	
Concentration (IU/liter)	3.3 (0.8–5.7)
Cycle day	13 (8–16)
Decrease	
IU/liter/day	0.4 (0.2–0.8)
Dominance ^a	
Follicle size (mm)	10 (6–15)
Cycle day	7 (3–15)
E ₂ concentration (pg/ml)	52 (25–112)
Preovulatory (day LH surge)	
Follicle size (mm)	21 (15–26)
E ₂ concentration (pg/ml)	236 (101–415)
Cycle day (LH surge)	16 (11–25)

[#] Blood sampling was performed daily. Transvaginal ultrasound was performed every 1–2 days. Median and range for cycle length was 28 (25–35) days. [Derived from Refs. 163, 206, and Schipper *et al.* (unpublished observations).]

^a Dominance is defined (published previously; Refs. 163, 206) as; 1) follicle largest in size as assessed by transvaginal ultrasound, 2) at least 2 mm larger as compared to remaining follicles, and 3) optical fit in growth curve of dominant follicles.

on cycle day 4) did elicit a significant rise in serum E₂ levels (Fig. 8) (171) (I. Schipper and B. C. J. M. Fauser, unpublished observations). Moreover, selection of a single dominant follicle is also prevented if high FSH levels are sustained in hyperstimulation protocols for IVF. The magnitude of multiple follicle growth in IVF patients has been shown to be proportional to the late follicular phase accumulation of FSH in serum (172). These experiments confirm that the duration (related to the window concept) rather than the magnitude (threshold concept) of FSH stimulation determines the number of developing follicles. We have recognized the crucial role of decremental serum FSH levels for single dominant follicle selection under normal conditions and have attempted to develop a decremental ('step-down') dose regimen for gonadotropin induction of ovulation for treatment of anovulatory infertility (see Section III.D) (Fig. 6, middle panel). It could be demonstrated, indeed, that growth of the dominant follicle is sustained despite reduced late follicular phase stimulation by decremental doses of exogenous FSH (173).

On the basis of previous studies it has been proposed that inhibin is an unlikely factor to play a significant role in dominant follicle feedback actions, since it appears that several antral follicles contribute equally to ovarian immunoreactive inhibin secretion. Moreover, inhibin serum levels did not differ in blood draining the ovary bearing the dominant follicle compared with blood from the contralateral ovary (174). Inhibin levels did not change during the early follicular phase. However, early inhibin immunoassays suffered from extensive cross-reactivity with potentially inactive precursors. Exciting new information has become avail-




FIG. 7. Follicular phase serum FSH levels (upper panel), maximum follicle diameter (mm) (middle panel), and E₂ levels (bottom panel) (mean and 95% confidence intervals) according to cycle day in 42 young volunteers with normal ovarian function. The dotted line in the middle panel indicates mean size of all observed follicles.

able recently since the development of new sandwich assays using monoclonal antibodies directed against the β B-subunit (the α -subunit combined with β B constitutes inhibin B) or against β A (inhibin A). Follicular phase serum patterns of inhibin A appear to be comparable to previously used less specific assays (175). In contrast, a profound rise in inhibin B serum levels was observed early in the follicular phase, suggesting that it is secreted by recently recruited cohort follicles in response to FSH. This rapid rise in inhibin B occurs just after the intercycle rise in FSH. It may be proposed that inhibin B limits the duration of the FSH rise (narrowing the FSH window) through negative feedback at the pituitary level and may therefore be crucial for mono follicle development. Elevated early follicular phase FSH levels in elderly ovulatory women were shown to be associated with decreased inhibin B secretion, which may be due to a reduced number of recruitable follicles in women of advanced reproductive age (176).




FIG. 8. Daily follicular phase FSH and E_2 serum levels (mean and SE) in 13 control cycles (○-○), after a single intramuscular injection of 600 IU FSH on cycle day 2 (●-●), 600 IU on day 2 plus 75 IU FSH daily from cycle day 4 onward (□-□), or 600 IU on day 2 plus 150 IU daily from cycle day 4 onward (■-■). Thirteen regularly cycling women were studied during four cycles. This study suggests that in the early follicular phase a distinct but short elevation of serum FSH levels above the threshold does not result in increased ovarian response. In contrast, ovarian activity is significantly enhanced due to a modest but extended mid- to late follicular phase increase in FSH (effectively widening the FSH window). [From Lolis DE, Tsolas O, Messinis IE. The follicle-stimulating hormone threshold level for follicle maturation in superovulated cycles. *Fertil Steril* 1995; 63:1272-1277; Reproduced with permission of the publisher, The American Society for Reproductive Medicine (formerly The American Fertility Society).]

3. *Dominant follicle development.* The ability to monitor growth of a large antral follicle, by means of transabdominal pelvic ultrasound, was originally described in an anovulatory patient during gonadotropin induction of ovulation (177). This noninvasive technique has allowed large-scale characterization of dominant follicle growth during the normal menstrual cycle (178-200). Follicles could be visualized from 8-10 mm onward (181), and usually two to three follicles per ovary could be identified (188, 189). Follicle size assessed by ultrasound has been compared with follicle volume as determined by the amount of fluid collected after puncture (182), or with follicle size during laparoscopy (190). Interobserver variability has been shown to be limited (200). Timing of ovulation could be predicted using ultrasound (180, 186, 187, 193), and the mean size of the preovulatory follicle reported in various studies ranged between 20 and 27 mm (201). On an individual basis, a high correlation was observed between follicle size and E_2 serum levels (179, 185). However, major individual variability in size of preovulatory follicles (191) results in linear regression, but low overall correlations between follicle size and serum E_2 levels (75, 163,

185, 188, 195, 199). Growth of the dominant follicle is generally mentioned to be linear, with a mean daily growth rate around 2-3 mm (163, 183).

Since 1985 the transvaginal route has been introduced for pelvic ultrasound (202, 203), allowing enhanced imaging resolution and a more reliable assessment of changes in number and size of small follicles (197). Growth of dominant and nondominant follicles has been studied extensively by our group using transvaginal sonography (TVS) (for review see Refs. 204 and 205). Up to 11 follicles (>2 mm in diameter) could be observed throughout the cycle in each ovary, and a dominant follicle could be visualized from 10 mm onward (Fig. 9) on cycle day 9 (Table 1). The size of nondominant follicles visualized by TVS always remains below 11 mm (163, 206). The ultrasound observation of dominant follicle selection correlates strongly with a sudden increase in serum E_2 concentrations ($r = 0.84$; $P < 0.001$), indicating that visualization of the dominant follicle coincides with enhanced E_2 synthesis (163), as has been shown previously by augmented E_2 levels in venous blood draining the ovary bearing the dominant follicle (88). This *in vivo* ultrasound observation also agrees fully with and extends previous studies (as discussed in Section II.B) showing that: 1) Aromatase activity *in vitro* is only observed if granulosa cells were obtained from follicles beyond 8 mm in size. 2) Augmented intrafollicular E_2 concentrations (and positive immunostaining of the P-450AROM enzyme) only in follicles beyond 10 mm. It could also be demonstrated that early follicular phase FSH levels decrease before the onset of a rise in serum E_2 concentrations (163, 204), which supports the notion that other ovarian factors (like for instance inhibin B) are to be held responsible for narrowing the FSH window.

F. Modulation of FSH action

In the previous section we have focused on the significance of patterns of serum FSH concentrations for follicle recruitment and selection. However, in addition to the quantity of hormone released by the pituitary, the FSH signal may also be altered by a difference in the distribution of various FSH isoforms, as well as by interference with FSH binding to the receptor, or by interference with postreceptor signal transduction by, for instance, growth factors. It may also be hypothesized that signal transduction after ligand binding may be influenced by the existence of various forms of transmembrane FSH receptors (so-called 'splice variants') (for review see Ref. 207).

1. *Heterogeneity of FSH.* Variant forms of FSH are synthesized and secreted by the anterior pituitary, on the basis of differences in oligosaccharide structure of these glycoproteins as well as the number of incorporated terminal sialic acid residues. FSH heterogeneity should be considered as a continuum of molecular forms, each with distinct physicochemical characteristics. Glycoprotein isohormones with different carbohydrate side chains can be separated by their differences in charge. Depending on the sophistication of techniques used, up to 20 isoforms have been characterized for human FSH. Heavily sialylated (more acidic) FSH has been described to exhibit reduced receptor binding and *in vitro*




FIG. 9. Diameters of individual ovarian follicles both in the dominant and contralateral ovary in a single regularly cycling woman. Day 0 represents the day of the LH surge (*left panel*). Rise in serum estradiol levels and growth of the dominant follicle were synchronized around the first day of visualization of the dominant follicle by TVS in 16 regularly cycling female volunteers (*right panel*). [From Pache TD, Wladimiroff JW, DeJong FH, Hop WC, Fauser BC. Growth patterns of nondominant ovarian follicles during the normal menstrual cycle. *Fertil Steril* 1990; 54:638–642; and van Santbrink EJP, van Dessel TJHM, Hop WC, DeJong FH, Fauser BCJM. Decremental follicle stimulating hormone and dominant follicle development during the normal menstrual cycle. *Fertil Steril* 1995; 64:37–43. Reproduced with permission of the publisher, The American Society for Reproductive Medicine (formerly the American Fertility Society).]

bioactivity, whereas circulating half-life of these forms is extended. These forms may be desialylated in the circulation. In contrast, basic isoforms have been described to be more biopotent *in vitro* (2- to 5-fold), whereas the circulating half-life is significantly reduced (for comprehensive reviews see Refs. 208 and 209).

Effects of estrogens on the *in vivo* isohormone profile of FSH have been repeatedly established. In fact, changes were found during the normal menstrual cycle, as well as after menopause. In a small number of women, more basic isoforms were described to be present at midcycle (210–212). Estimates of changes in FSH heterogeneity, as assessed by *in vitro* bioassays, during the menstrual cycle are contradictory (210, 213, 214) and appear to be dependent on the assay system used. It has been speculated that ovarian follicles are recruited in the early follicular phase (when gonadal steroid feedback is low) predominantly by more acidic FSH isoforms, whereas follicle selection and rupture later during the

follicular phase is dependent chiefly on more basic FSH isoforms. However, the net effect of a predominance of more bioactive but shorted half-life forms on the overall *in vivo* biopotency is unknown at this stage, and therefore the physiological significance of described changes in FSH isoforms remains open for speculation.

2. *Direct interference with FSH action.* It has been proposed that low molecular weight proteins specifically interfering with FSH receptor binding are present in serum (215). In addition, a high molecular weight FSH receptor binding inhibitor was partially purified from human follicle fluid by the same group of investigators (216). However, these proteins have never been fully characterized, and the physiological relevance remains uncertain (for review see Ref. 207). Cell lines transfected with the human FSH receptor may prove a valuable tool with which to study further the pathophysiological relevance of inhibition of FSH receptor activation (217–219a).

3. *Intraovarian interference with FSH action by growth factors.* Serum FSH concentrations are maximal in the early follicular phase of the menstrual cycle. In contrast, circulating E_2 levels start to rise around the midfollicular phase coinciding with the visualization of a dominant follicle by ultrasound. E_2 production, however, can be stimulated rapidly *in vitro* by adding FSH to the culture medium (59, 68, 92), and it cannot be readily explained why early follicular phase E_2 levels remain low despite maximum FSH stimulation (163). The lag period between maximum FSH stimulation and augmented ovarian E_2 output may be explained by intraovarian inhibition of FSH action early in the follicular phase or enhancement of FSH action within the dominant follicle (Fig. 10). The dominant follicle continues to mature despite decreased stimulation by lower late follicular phase FSH concentrations. This observation of decreased dependence of the dominant follicle on FSH stimulation (as discussed extensively in Section II.E) strongly suggests that the FSH signal is modified within the ovary, either at the level of FSH binding to the

receptor or by interference with postreceptor signal transduction. In addition, the intrafollicular rise in E_2 levels of the dominant follicle was believed to be responsible for the decreased need for stimulation by FSH through autocrine short loop up-regulation (220). However, it is now clear that follicles can mature fully without a concomitant rise in E_2 . This observation strongly suggests that other (intraovarian) factors in fact drive growth of the follicle, and disturbed intraovarian regulation may prove to be crucially important for cessation of follicle development in PCOS patients. Moreover, a 2.5-fold difference in maximum early follicular phase FSH serum concentrations — not correlated with any other follicular phase parameter, such as length or follicle growth characteristics (163) — observed in a group of young women presenting with normal ovarian function suggest distinct differences in the individual FSH threshold. This observation implies differences in intraovarian regulation under normal conditions.

After initial studies regarding effects of different growth factors on FSH-stimulated granulosa cell function *in vitro* (for review see Ref. 221), numerous studies have been undertaken regarding the potential physiological significance of growth factors for intraovarian modification of FSH action (12, 164, 222–225). The majority of growth factors, such as insulin-like growth factors (IGF) (226), transforming growth factor- β , fibroblast growth factor, and activin (227), have been shown to enhance FSH action *in vitro*. In contrast, other growth factors have been shown to inhibit FSH-stimulated E_2 biosynthesis by cultured human or primate granulosa cells, including inhibin (228), epidermal growth factor (229–231), and IGF binding protein (IGFBPs) (232). Decreased follicle fluid epidermal growth factor and transforming growth factor- α concentrations have been described when follicles mature (233–235). Moreover, white blood cell-derived cytokines, such as like tumor necrosis factor, interferon, or interleukins, have been proposed to be relevant for human ovarian physiology (236).

Certainly, overwhelming evidence is available regarding major changes in the IGF system during follicle development in the human ovary (237). Expression of IGF-II and their binding protein (IGFBPs), as well as IGF receptors, has been shown to be dependent on the developmental stage of the follicle (238, 239). IGFBP-3 was shown to exhibit structural similarity with the FSH-binding inhibitor (240), and the IGFBP profile in follicle fluid has been described to vary during follicle development, independent from changes in serum (241). Moreover, proteases capable of specifically decreasing the level of IGFBP-4 could be demonstrated in estrogen-dominant follicle fluid only (242), suggesting that more bioavailable IGF-II is available to synergize with gonadotropins in the dominant follicle. It should be noted, however, that growth of follicles could be induced by exogenous FSH in a patient with Laron-type dwarfism (low endogenous IGF-I secretion due to a familial GH receptor defect) (243), suggesting that IGF-I is not required for normal ovarian function. Conclusive *in vivo* evidence that any of the above mentioned growth factors play a distinct role in human ovarian physiology is lacking as yet.





FIG. 10. Schematic representation of potential modification of FSH action within the ovary, being either inhibitory in the early follicular phase, or stimulatory in the late follicular phase (*top panel*), and growth factors potentially involved in late follicular phase enhancement of FSH action (*bottom panel*).

III. Gonadotropin Induction of Ovulation

A. The concept of monofollicle growth in anovulatory patients

Exogenous gonadotropins have been widely used for the treatment of anovulatory infertile women since 1958 (for comprehensive reviews see Refs. 244–250). Although commercially available gonadotropin preparations are generated through extraction of human urine, the first described application involved gonadotropins obtained from human pituitaries (251). HMG preparations (FSH to LH activity ratio, 1:1), obtained from urine of postmenopausal women, are administered to stimulate follicle growth, whereas pregnant women provide the urine source for hCG preparations (with LH-like activity) to induce ovulation. During the first decade of clinical use, various dose regimens, such as fixed, intermittent, or flexible incremental or decremental doses, have been tested (252, 253). It should be realized that at that time ovarian response could only be estimated by indirect measures, such as palpation of ovarian size or assessment of cervical mucus production resulting from ovarian estrogen secretion. Tools to measure ovarian response after exogenous FSH have improved considerably over the years.

The great majority of anovulatory patients presently treated with gonadotropin preparations comprise normogonadotropic (*i.e.* normal serum FSH concentrations; World Health Organization, class II) anovulatory infertile women who failed to conceive during previous antiestrogen medication. The aim of this treatment modality is to approach normal conditions as closely as possible; *i.e.* maturation and ovulation of a single dominant follicle and subsequent singleton pregnancy. Characteristics of dominant follicle development during gonadotropin induction have been documented using ultrasound and serum estrogen assays (254–257). It should be stressed that the goal of induction of ovulation is completely different from 'controlled' ovarian hyperstimulation for IVF, where the goal is to interfere with selection of a single dominant follicle to obtain multiple oocytes for IVF. Therefore, the use of the term induction of ovulation for IVF is confusing and should be abandoned.

Although gonadotropin therapy has been shown to be fairly successful in terms of ovulation rates (reported in the literature between 60–100%) and cumulative pregnancy rates (reported between 20–75%), complication rates are high. Major complications include multiple pregnancies (258), ovarian hyperstimulation (259), and a high rate of early pregnancy wastage (260). The first two complications have been shown to be related to the magnitude of multiple follicle development as estimated by serum estrogen levels (261–263) and more recently by pelvic ultrasound (264). The high abortion rate has been suggested to be related to elevated LH levels (265, 266). In addition, a significant increase in the overall prevalence of multiple pregnancies over the last 10–20 yr has been established repeatedly in the literature (267–271), and gonadotropin induction of ovulation is certainly involved. Inherent problems include social difficulties, ethical considerations regarding fetal reduction (272, 273), perinatal morbidity, and increased health care costs (274).

A great individual variability in ovarian response to stim-

ulation by FSH (so-called 'FSH threshold') was proposed in anovulatory patients (151). Moreover, Brown (151) stressed that only a small margin exists between an effective dose and a dose generating excessive ovarian response. Unfortunately, predictors for the FSH threshold of a given patient have not been identified. The concept of the FSH threshold in anovulatory patients was substantiated more recently (152, 153) with the use of intravenous administration of exogenous gonadotropins by pump. The threshold level was arbitrarily extrapolated from the first day a follicle beyond 12 mm could be observed by transabdominal ultrasound or TVS. No difference in the FSH threshold was observed, comparing HMG *vs.* FSH. Moreover, a 2-fold variation in individual threshold levels was observed, and higher FSH serum levels above the assessed threshold were found to be associated with multifollicular growth (Fig. 5). Major individual variability in response to stimulation by exogenous FSH underscores the need for careful and frequent monitoring of ovarian response by ultrasound and/or rapid serum E₂ assays (257) and adjustment of doses on an individual basis. In general, the focus is to approach the individual threshold level prudently, to prevent serum FSH concentrations to increase far above the threshold. Differences in the FSH threshold level result in considerable variability in the duration of gonadotropin administration in the event that low initial doses are administered. Unaltered late follicular phase FSH serum levels in gonadotropin-induced cycles differ greatly from the follicular phase of the normal menstrual cycle. This condition may elicit growth of other cohort follicles and, as a result, induce multiple follicle development.

During the interphase from one menstrual cycle to the other, serum FSH concentrations surpass the threshold for stimulation of ongoing and gonadotropin-dependent follicle development. Serum FSH levels decrease steadily during the follicular phase, securing the formation of a single dominant follicle. Only this follicle reaches the full mature state despite diminished stimulation by FSH, whereas growth of the remaining less mature follicles in the cohort ceases due to insufficient support by FSH. The significance of this pattern of FSH stimulation is stressed by various intervention studies, both in the human and in the monkey model, as discussed extensively in *Sections II.D* and *II.E*. The threshold concept for induction of ovulation focuses only on the magnitude of ovarian stimulation by FSH, but ignores the element of time. In contrast, the FSH window concept emphasizes the importance of FSH concentrations surpassing the threshold for a limited period of time only. Decremental dose regimens for exogenous FSH may be more effective in inducing preferential growth of the leading follicle (Fig. 6, *middle panel*). This approach may have implications for gonadotropin induction of ovulation, as discussed later in this section. In addition to the gonadotropin dose, many other factors may influence treatment outcome. These conditions will first be discussed.

B. Conditions affecting treatment outcome

1. *Patient-related factors.* Women diagnosed as hypogonadotropic hypogonadism, by definition, suffer from inadequate stimulation of ovarian function. FSH serum levels are below

the threshold, and growth of follicles is arrested at a stage where further development becomes dependent on stimulation by gonadotropins. If FSH levels rise above the threshold, due to exogenous administration of gonadotropin preparations, ovarian response should be normal. Success and complication rates of gonadotropin induction of ovulation in these patients is indeed favorable (275–281). However, the great majority of patients presently treated with gonadotropins present with clomiphene-resistant normogonadotropic anovulation. Serum FSH and E_2 levels in these patients are within normal limits. Obviously, normal limits for both FSH and E_2 depend heavily on the phase of the menstrual cycle. As mentioned previously, maximum early to mid follicular phase FSH levels are twice as high as late follicular phase concentrations (see also Table 1). Moreover, even in young regularly cycling women the FSH threshold varies considerably (at least 2-fold). This variability is poorly recognized in the classification of anovulation on the basis of serum FSH assays. For a given anovulatory woman, FSH levels 'within the normal range' may simply mean FSH levels below the threshold for ovarian stimulation. Hence, only the intercycle rise in FSH above the threshold may be lacking in these patients.

Normogonadotropic anovulatory women frequently suffer from PCOS. This heterogeneous group of patients is characterized by ovarian abnormalities (polycystic ovaries) combined with distinct endocrine features (elevated serum LH and/or androgen levels) (282). Various lines of evidence indicate that early follicle development is normal in these patients, whereas anovulation is caused by disturbed dominant follicle selection (74). This abnormal condition may be caused by disturbed intraovarian regulation of FSH action (129), and therefore response to exogenous FSH may be different from normal. Hence, the presence or absence of ovarian abnormalities in patients may influence treatment outcome after exogenously administered gonadotropins. This may explain major differences in the FSH threshold and duration of stimulation needed to induce preovulatory follicle development in these patients.

Presently, the wish to establish a family is expressed later in life. Therefore, the population of women seeking help for infertility is increasing in age. It has been documented that cumulative conception rates after gonadotropin induction of ovulation are distinctly different when women under the age of 35 are compared with older women (276, 280).

Obesity frequently coincides with PCOS, and differences in pharmacokinetic characteristics of gonadotropin preparations (283), as well as clinical outcome (284, 285) related to body weight, have been reported. Moreover, other concomitant endocrine disorders such as hyperprolactemia or adrenal hyperandrogenemia may also affect treatment outcome.

2. Hormone preparation-related factors. Preparations of urinary gonadotropin have been continuously improved since its commercial introduction. HMG preparations contain similar (1:1 ratio) FSH and LH activity, as required by regulatory agencies (286, 287). The most significant improvements of HMG preparations over the years involved the introduction of 1) purified urinary FSH (with only minute amounts of LH),

2) highly purified urinary FSH (obtained through an affinity extraction procedure, removing virtually all of the contaminating proteins) (288), and 3) human recombinant FSH preparations (113, 289–291). Other recombinant glycoprotein preparations — such as recombinant hCG (292), LH (293), long-acting FSH (FSH-CTP) (294), short-acting (deglycosylated) FSH (295), and single-chain gonadotropins (296) — will be available soon. This fascinating development certainly provides the clinical investigator with a whole new set of tools with which to manipulate ovarian function. Moreover, the clinician will have the unique and challenging opportunity to tailor compounds and corresponding circulating half-lives according to the treatment goal and the individual needs of the patient. Different host cells produce recombinant FSH with different isohormone profiles (297). Therefore *in vivo* biopotency of a given distribution of FSH isoforms may vary. However, it is uncertain at this stage whether this approach may result in improved treatment outcome.

Since elevated LH levels are believed to be involved in poor reproductive outcome, many studies have been undertaken to test whether the administration of urinary FSH, as compared with HMG, may improve treatment outcome in PCOS patients. However, all published comparative trials have failed to show such an effect (298–301). Considerable batch-to-batch differences have been observed for urinary gonadotropin preparations (302–304), and therefore the amount of bioactive FSH administered may vary from patient to patient, or from cycle to cycle within the same patient. Clinicians should be aware of the fact that a clear discrepancy may occur between the number of ampoules administered and the amount of circulating bioactive FSH actually stimulating the ovaries. Differences in the isohormone profile of various preparations — with a predominance of more acidic or basic forms — may be involved (208, 209). Unfortunately, few studies have been undertaken focusing on immunoreactive and bioactive FSH levels and ovarian activity during gonadotropin induction of ovulation in a clinical setting.

It appears that the route of administration (being either intraperitoneal or subcutaneous) does not represent a major factor in determining clinical outcome, although solid comparative studies have not yet been published. Some pharmacokinetic differences have been observed comparing both routes of administration (305). Patient convenience is certainly served using the subcutaneous administration route.

3. Other factors involved. Probably the most important single factor determining success and complication rates for gonadotropin induction of ovulation is response monitoring of the ovary. Presently, this can be performed through frequent TVS scanning of number and size of developing follicles, and rapid serum E_2 assays. Aims of ovarian monitoring are to assess the effective FSH dose, duration of FSH medication, timing of hCG to induce ovulation, and finally prevention of multiple follicle development. Correlations between serum E_2 levels and number and size of follicles have been studied (194, 306), and it was shown that E_2 production is the net result of all developing follicles. This is in sharp contrast to normal follicle development where estrogens are produced by a single dominant follicle only. It should also be realized

that the previously established correlation between follicle development and E_2 levels during gonadotropin induction of ovulation may change in the event that recombinant FSH is used instead of urinary gonadotropin preparations (115). There is ongoing debate whether ultrasound alone may suffice or whether both monitoring techniques should be combined to secure maximum safety (194, 263, 307–309). Various reports have emphasized the possibility of predicting chances for multiple pregnancies or ovarian hyperstimulation by ultrasound alone (264). However, high E_2 levels are associated with increased chances for ovarian hyperstimulation regardless of ultrasound findings (173, 306).

Concomitant medication, in addition to gonadotropins, may include: 1) dexamethasone suppression of adrenal androgen production (310); 2) GnRH agonists to suppress endogenous release of LH (and FSH) (311, 312); 3) dopamine agonists therapy in case of hyperprolactinemia; 4) GH in an attempt to improve ovarian responsiveness (313); and 5) luteal support either by hCG or progestins. The concept of the adjuvant administration of GH is appealing and represents an innovative attempt to transpose the concept of intraovarian regulation to clinical practice. Hsueh and colleagues showed in the rat model that GH augmented intraovarian IGF-I production (314) and granulosa cell differentiation (315). However, it was shown more recently that species differences exist, and that human granulosa cells exclusively produce IGF-II. Although amplification of gonadotropin action on the ovaries by GH could be repeatedly demonstrated in the human, these studies have failed to clearly establish an improvement of treatment outcome (316–318). All in all, none of the above mentioned options improved pregnancy rates in prospective randomized comparative trials.

The amount of hCG administered to induce ovulation may also vary. Ovarian hyperstimulation does not occur if hCG is withheld, and therefore various investigators have focused on triggering ovulation by other means such as GnRH or GnRH agonists in an attempt to reduce hyperstimulation rates (319). Moreover, recombinant LH with a shorter half-life will soon be available to trigger ovulation (293), which may also reduce chances of hyperstimulation.

There are several other factors that may affect treatment results but that are usually ignored when differences in outcome of various studies are compared. First line therapy of normogonadotropic anovulatory women usually involves anti-estrogen medication, and gonadotropin medication is only applied in case of 'clomiphene resistance.' This term, however, is poorly defined in the literature and a major discrepancy exists between doses applied and number of months treated. When cumulative pregnancy rates are reported, the duration of gonadotropin treatment (number of cycles included per patient) varies considerably (reported between 3 and 12 months) (for review see Ref. 249).

C. Commonly used step-up dose regimen

1. *Conventional step-up protocol.* Conventional step-up dose regimens for gonadotropin induction of ovulation are characterized by initial daily doses of two ampoules (= 150 IU of bioactive FSH). Doses may be increased after 5 days in the event that ovarian response is judged to be insufficient. This protocol has been the preferred dose regimen world wide since the early 1970s. Estimation of ovarian response changed over time from physical examination to (urine and later serum) estrogen assays, to abdominal ultrasound, and more recently TVS. Improved accuracy of response monitoring resulted in superior treatment outcome. For more detailed information regarding reported success and complication rates of this conventional high-dose regimen, see Table 2. Again, these data should be interpreted with great caution since patient diagnosis and age, response monitoring, and duration of therapy may vary from study to study. Collectively, these data suggest that this treatment modality is effective, with a relatively high complication rate (253, 275–279). This is now believed to be related to FSH serum levels being too far above the threshold in a great proportion of patients. However, few studies have focused on FSH serum levels and ovarian response during conventional step-up cycles (320–322).

2. *Low dose, step-up protocol.* Although originally developed on the East coast of North America (323), the low-dose

TABLE 2. Clinical outcome of conventional step-up regimens for gonadotropin induction of ovulation (starting dose 2 ampoules/day) in normogonadotropic anovulatory infertile women

	Author, published year, ref. no.					
	Thompson and Hansen, 1970 (253)	Oelsner <i>et al.</i> , 1978 (275)	Dor <i>et al.</i> , 1980 (276)	Healy <i>et al.</i> , 1980 (277)	Schwartz <i>et al.</i> , 1980 (278)	Wang and Gemzell, 1980 (279)
Patient diagnosis	PCO	WHO II	WHO II	WHO II	WHO II	PCO
No. of patients	212	318	348	40	88	41
No. of cycles	546	^a	1137	159	249	77
Ovulatory cycles (%)	62	^a	^a	93	98	97
Conceptions						
per started cycle (%)	10	^a	^a	^a	^a	^a
per ovulatory cycle (%)	^a	^a	^a	^a	20	^a
Cumulative pregnancy rate (%)	26	21	50	75	45	66
Multiple pregnancy rate (%)	17	16	^a	25	15	36
Abortion rate (%)	39	42	^a	10	33	24
Hyperstimulation rate (%) ^b	1.1	4	^a	14	1.4	12

PCO, Polycystic ovaries; WHO II, World Health Organization, class II (defined as normal serum gonadotropin and/or normal E_2 levels).

^a No information provided.

^b No uniform classification.

step-up regimen for gonadotropin induction of ovulation has been the preferred method of stimulation in Europe since 1990. This dose regimen is characterized by low initial daily gonadotropin doses ranging between one-half and one ampoule (38–75 IU of bioactive FSH), and doses are only increased by one-half ampoule per day after 14 days, in cases of insufficient ovarian response. See Table 3 for more detailed information regarding reported success and complications of this dose regimen. Overall, this treatment modality seems to be characterized by low complication rates, at the price of an extended duration of treatment and possibly a slightly diminished success rate (323–334).

This treatment modality is aiming at slowly and prudently reaching the FSH threshold for stimulation of ovarian activity, in an attempt to reduce the magnitude of serum FSH levels surpassing the individual threshold (335). As mentioned previously, the individual FSH threshold may vary considerably. This means that in a given patient, gonadotropins are administered for an extended period of time, and the amount is only augmented after 14 days of treatment in the event that a relatively high FSH threshold is operative. Pharmacokinetic studies have indicated that it takes approximately 5 days before steady state FSH levels are reached when similar gonadotropin doses are administered daily through the intraperitoneal route (283, 336). Therefore patients may be exposed to FSH levels that are too low to stimulate follicle growth for several weeks. It is uncertain whether ovaries may be sensitized by extended exposure to subthreshold FSH levels. Similar daily serum FSH levels were measured preceding hCG administration in patients treated with low-dose, step-up protocols (330) (E. J. P. van Santbrink and B. C. J. M. Fauser, unpublished observations). Hence, in the late follicular phase FSH serum levels remain above the threshold for an extended period of time, resulting in a wide FSH window even when low-dose step-up protocols are used. Improved treatment outcome, as compared with conventional step-up protocols, is likely due to the reduced magnitude of FSH levels surpassing the threshold when lower initial doses are used. Improved monitoring of ovarian response should not be ruled out as an additional

important factor responsible for improved safety of treatment.

On the basis of preliminary findings it has been suggested that late follicular phase serum FSH levels diminish due to increased E₂ negative feedback *only* in a subset of patients exhibiting monofollicle development (153, 337). Observed differences in late follicular phase FSH concentrations comparing patients presenting with monofollicular *vs.* multifollicular development (337) suggest again that the magnitude of FSH accumulation, which seems unpredictable even during low-dose regimens, determines individual response. The conclusion seems justified that late follicular phase estrogen steroid feedback is overruled to a variable degree in patients treated with low-dose step-up gonadotropin doses.

D. Potential for a step-down dose regimen

Zelevnik and co-workers (145) studied the significance of decreasing FSH serum levels for single dominant follicle selection in the monkey model. Histological examination of ovaries 5 days after passive immunization of monkeys with estradiol antibody infusion revealed the presence of two or more large follicles, suggesting that interference with the FSH-suppressive actions of E₂ results in continued maturation of secondary follicles. Moreover, GnRH antagonist-treated monkeys were infused with human LH and FSH. The LH dose was kept constant and FSH doses were increased every 3–4 days until serum E₂ levels rose. Subsequent reduction of the FSH amount with 12.5% per day for 5 days was accompanied by continued follicle development and a further rise in serum E₂ levels (Fig. 4) (143). These *in vivo* observations indicate a reduced need of the dominant follicle for FSH, since this follicle continues to mature despite relatively low FSH levels, incapable of stimulating growth of less mature follicles. Another study focused on cumulative ovulation rates in HMG-treated monkeys comparing a step-up and a step-down protocol (338). Most ovulations were found to occur before day 3 after hCG administration when the step-down protocol was used. However, additional follicles ruptured on days 4 and 5 when a step-up protocol

TABLE 3. Clinical outcome of low-dose step-up regimens for gonadotropin induction of ovulation (starting dose 1/2–one ampoule/day) in clomiphene citrate-resistant anovulatory infertile women, diagnosed as polycystic ovary syndrome

	Author, published year, and ref. no.							
	Seibel <i>et al.</i> , 1984 (323)	Buvat <i>et al.</i> , 1989 (324)	Hamilton-Fairley <i>et al.</i> , 1991 (325)	Dale <i>et al.</i> , 1993 (330)	Herman <i>et al.</i> , 1993 (331)	Balen <i>et al.</i> , 1994 (332)	Strowitzki <i>et al.</i> , 1994 (333)	Homburg <i>et al.</i> , 1995 (334)
Patient diagnosis	PCO	PCOS	PCOS	PCOS	PCOS	PCOS	PCOS	PCOS
No. of patients	5	23	100	50	30	103	20	25
No. of cycles	6	44	401	66	75	603	27	59
Ovulatory cycles (%)	66	70	72	74	96	68	93	79
Conceptions								
per started cycle (%)	^a	16	^a	18	^a	14	26	17
per ovulatory cycle (%)	^a	23	^a	22	19	20	28	24
Cumulative pregnancy rate (%)	50	^a	55	^a	47	72	35	40
Multiple pregnancy rate (%)	^a	0	4	^a	21	18	28	0
Abortion rate (%)	^a	14	32	33	^a	16	0	30
Hyperstimulation rate (%) ^b	^a	5	4	3	4	8	15	0

PCO, Polycystic ovaries; PCOS, polycystic ovary syndrome.

^a No information provided.

^b No uniform classification.

was applied, and it was concluded by the authors that follicle maturation was better synchronized resulting in a narrow 'ovulatory window' with a step-down protocol.

On the basis of physiological considerations (as discussed in Section II.E) and the above mentioned studies performed in the monkey, our group has focused on establishing a protocol for gonadotropin induction of ovulation applying decremental doses once ovarian response is established (so-called 'step-down' protocol) (169, 170). The major goal has been to design a safe and effective dose regimen for gonadotropin induction of ovulation that approximates physiological circumstances as closely as possible (173, 339–341). During initial studies only, patients were cotreated with a GnRH agonist in an attempt to reduce chances of interference of exogenously administered gonadotropins with unpredictable changes in endogenous FSH release. Using a regimen of two ampoules/day with two decreasing steps of one-half ampoule, daily blood sampling revealed that serum FSH levels showed a 2.1-fold increase followed by a subsequent decrease of 10% per day for 4 days (173), remarkably similar to previous studies in the monkey (143). Growth of follicles was sustained and ovulation achieved in the great majority of patients using this step-down regimen. The observed major variability in early follicular phase increase in serum E_2 (representing differences in the FSH threshold for stimulation of ovarian activity) was shown to predict chances for ovarian hyperstimulation. In a subsequent study (341) both immunoreactive and bioactive serum FSH concentrations were compared between step-down gonadotropin induction of ovulation and regularly cycling volunteers. Similar maximum follicular phase FSH concentrations were noted as well as similar late follicular phase daily FSH decreases. However, late follicular phase levels are lower due to a greater number of days of decreasing FSH levels during the normal menstrual cycle (median 7 vs. 4 days) (see also Fig. 11, and Table 4). It should be emphasized that daily blood samples were drawn 24 h after the previous injection. Pharmacokinetic studies of exogenous gonadotropins (336) revealed maximum FSH serum levels approximately 6–8 h after injection, and maximum levels were estimated to be approximately 30% higher as compared with 24 h concentrations. This opposes normal conditions where only minimal FSH changes during the day have been reported (342). In case of monofollicle development during step-down gonadotropin protocols, growth rate and E_2 production by the dominant follicle is identical to those of the normal menstrual cycle (340).

Initial dose finding studies have generated a dose regimen that can be used in clinical practice. We have abandoned the use of GnRH agonists since 1992 without any loss of clinical efficacy. A similar FSH dose regimen is applied; *i.e.* a two-ampoule/day starting dose shortly after a spontaneous or progestagen-induced bleeding, followed by a decrease to one and one-half ampoules/day once a dominant follicle can be visualized by TVS (at least one follicle ≥ 10 mm). The dose is further decreased to one ampoule/day 3 days after the first dose reduction. See Table 5 for a summary of our clinical results in 234 cycles (343). Only one or two large preovulatory follicles were observed in 95% of stimulated cycles, and the median duration of treatment was 10 days (Fig. 12). Comparison of the group of women who did or did not conceive




FIG. 11. Follicular phase serum FSH levels (*upper panel*), maximum follicle diameter (mm) (*middle panel*), and E_2 levels (*bottom panel*) (mean and 95% confidence intervals) according to medication day in 22 women with normogonadotropic anovulatory infertility during gonadotropin induction of ovulation using a step-down dose regimen. The dotted line in the middle panel indicates mean size of all observed follicles. Patients were pretreated for 3 weeks with a GnRH agonist (Buserelin; 1200 μ g/day, intranasally) and medication was continued until hCG administration. The starting dose of gonadotropins was two ampoules (= 150 IU FSH)/day intramuscularly. The dose was decreased to one and one-half ampoules/day when at least one follicle ≥ 10 mm could be visualized, and to a final dose of one ampoule/day 3 days later. [Derived from Refs. 173 and 341.]

during treatment showed no significant differences with regard to body weight as well as initial serum LH and T levels, which appears to be different from observations using the low-dose, step-up regimen. The observed reduction in the duration of stimulation, as well as a lower total number of ampoules per stimulation cycle, may represent significant benefits in terms of health economics (reduced drug costs per cycle, possibly a reduced number of visits to the clinic, and more ovulations in a given time period). See Table 6 for a

TABLE 4. Endocrine and sonographic characteristics of the follicular phase during gonadotropin induction of ovulation using a decremental dose regimen, in 22 clomiphene-resistant normogonadotropic anovulatory women[#]

	Median (range)
Day 1 of medication	
FSH concentration (IU/liter)	3.6 (0.9–6.3)
E ₂ concentration (pg/ml)	31 (12–72)
Follicle diameter (mm)	3 (2–4)
FSH	
Maximum	
Concentration (IU/liter)	7.6 (3.9–10.9)
Medication day	4 (1–9)
Minimum	
Concentration (IU/liter)	4.7 (2.7–8.2)
Medication day	7 (4–12)
Decrease	
IU/liter/day	1.5 (0.5–6.6)
Dominance (at least one follicle ≥ 10 mm)	
Cycle day	4 (2–7)
E ₂ concentration (pg/ml)	296 (54–866)
Preovulatory (day of hCG administration)	
Follicle size (mm)	19 (18–21)
E ₂ concentration (pg/ml)	488 (76–3016)
Medication day	8 (5–12)

In these studies patients were pretreated for 3 weeks with a GnRH agonist (Buserelin; 1200 µg/day, intranasally) and medication was continued until the day of hCG administration. HMG doses administered were two ampoules (= 150 IU FSH)/day as the starting dose, followed by decreasing daily doses of one and one-half ampoules/day (after dominance) and one ampoule/day (3 days later), intramuscularly. Blood sampling was performed daily. [Derived from Refs. 173 and 341.]

TABLE 5. Clinical outcome of step-down regimens for gonadotropin induction of ovulation (starting doses two to three ampoules/day) in clomiphene citrate-resistant normogonadotropic anovulatory infertile women

	Author, published year, ref. no.	
	Mizunuma <i>et al.</i> , 1991 (345)	van Santbrink <i>et al.</i> , 1995 (343)
Patient diagnosis	PCOS	WHO II
No. of patients	9	82
No. of cycles	17	234
Ovulatory cycles (%)	100	91
Conceptions		
per started cycle (%)	29	16
per ovulatory cycle (%)	29	17
Cumulative pregnancy rate (%)	^a	47
Multiple pregnancy rate (%)	20	12
Abortion rate (%)	^a	19
Hyperstimulation rate (%)	^a	2 ^b


PCOS, Polycystic ovary syndrome; WHO II, World Health Organization, class II (defined as normal serum FSH and normal E₂ levels).

^a No information provided.


^b Mild cases only.

summary of major findings regarding the step-down protocol. It is too early to draw final conclusions regarding success and complication rates of this treatment modality. Clearly, only randomized comparative trials with sufficient statistical power can eventually determine whether the step-down approach represents a realistic alternative for every day practice of gonadotropin induction of ovulation.

Various other attempts pointing in the same direction have been published in the literature. Growth of the dominant



TREATMENT PHASE DURATION



AMOUNT OF AMPOULES PER CYCLE




FIG. 12. Distribution of number of follicles larger than 16 mm (*upper panel*), duration of treatment (from day 1 of gonadotropin administration until 1 day after hCG injection) (*middle panel*), and required number of ampoules of gonadotropins per cycle (*bottom panel*) in 213 ovulatory cycles after gonadotropin induction of ovulation using a step-down dose regimen in 82 normogonadotropic clomiphene-resistant anovulatory women. In this clinical study no GnRH agonist comedication was used. [Adapted with permission from E. J. P. van Santbrink *et al.*: *Hum Reprod* 10:1048–1053, 1995 (343).]

follicle could be sustained in a woman with hypogonadotropic hypogonadism when exogenous FSH doses were decreased by 10% per day for 4 days after increased estrogen secretion (344). Clinical results of a step-down regimen in 22 PCOS patients, applying initial doses of three ampoules/day, with a reduction of the daily dose to one ampoule/day on day 3 (345) are also summarized in Table 5. Preliminary results (346) concerning a large multicenter study (involving 175 patients) comparing a step-up and a step-down regimen (initial dose three ampoules/day) in a prospective randomized fashion have been reported in abstract form. This study suggested a similar number of large preovulatory follicles comparing both treatment groups, a reduced preovulatory

TABLE 6. Summary of major findings regarding the step-down dose regimen (initial doses two ampoules/day, followed by two decreasing steps to one and one-half and one ampoule/day) for gonadotropin induction of ovulation

FSH profile resembles FSH levels during the follicular phase of the normal menstrual cycle
Safe and effective clinical use has been established in an uncontrolled, single-center study
Short duration of treatment and low number of ampoules per stimulated cycle, is user friendly, and may suggest health economics benefits
Absence of apparent effects of obesity and elevated initial LH levels on treatment outcome
Major individual variability in ovarian response suggest differences in the FSH threshold. A starting dose of two ampoules/day is too high for some patients
Potential for further improvement of efficacy and safety

E_2 level in the latter group, and similar ovulation and cancellation rates. There were no differences in multiple pregnancy and hyperstimulation rates. However, for unknown reasons the pregnancy rate was significantly reduced after the step-down protocol. Unfortunately, this study was never reported in full detail, and the question whether the particular dose regimen used should be held responsible for observed differences remains unanswered. Preliminary results applying a sequential step-up and step-down regimen in 20 PCOS patients were reported recently (initial daily dose varied from one to one and one-half ampoules, and doses were subsequently reduced again to one ampoule daily after the leading follicle had reached a diameter of 14 mm) (347). As compared with step-up protocols, a significant reduction in late follicular phase E_2 levels and number of large and medium-sized follicles was observed. Another interesting approach is the use of sequential treatment with FSH (starting dose two ampoules/day), followed by pulsatile GnRH administration (20 μ g pulses, subcutaneously, every 120 min) when the follicle reached a diameter of 11 mm. Results in 18 hypogonadotropic anovulatory patients were reported recently (348). Late follicular phase serum FSH levels were greatly diminished when pulsatile GnRH was applied, again resulting in a significant reduction in the number of large preovulatory follicles (1.3 *vs.* 3.9).

IV. Steroid Contraception and Residual Ovarian Activity

A. The concept of follicle growth during partial and transient suppression of circulating FSH

Oral contraceptives inhibit ovarian activity and ovulation through negative feedback actions of administered synthetic steroids on the hypothalamic-pituitary axis (349). The estrogen compound is believed to primarily inhibit FSH secretion, whereas progestins are supposed to mainly inhibit LH. Key effects of progestins involve reducing the frequency of the hypothalamic GnRH pulse generator (350). However, the contention of disparate effects of steroids on gonadotropin release has not been carefully investigated, and studies comparing the effects of estrogens alone *vs.* estrogen/progestin combinations on pituitary-ovarian function are lacking. Steroid contraception is well tolerated, exceptionally effective,

and extensively used worldwide. In an attempt to reduce side effects and to diminish the potential for short and long-term complications, estrogen doses have been gradually reduced. Since the introduction of oral contraceptives in the early 1960s, daily doses of ethinylestradiol (EE) in commercially available preparations have been diminished from 150 to 20 μ g. Combined steroid pills with EE doses as low as 10 μ g/day have proven effective when medication is taken correctly (351). Combined steroid contraceptives containing 1 mg of micronized estradiol have also been shown to inhibit ovulation, although control of bleeding was insufficient (352). In addition, novel, so-called second and third generation, progestins with reduced androgenic side effects have been developed and introduced in contraceptive regimens (353). Progestins may be combined with estrogens or may be administered alone. Progestin only (oral and depot) preparations have been tested extensively in recent years to provide women with the alternative of estrogen-free contraceptives. However, reduced suppression of pituitary FSH release introduced the need for continued progestin medication, which negatively affects cycle control.

Although pill effectiveness has not been compromised substantially, diminished suppression of circulating FSH by reduced steroid doses may give rise to substantial residual ovarian activity, as well as reduced tolerance for pill omission or for other circumstances that reduce circulating steroid concentrations (354–356). Follicle growth and concomitant E_2 production usually occur during the pill-free interval and the first week of pill intake, or when tablets are missed. Pill omission has been reported to occur in a substantial proportion of pill users in everyday practice (up to 27% of women in a 3-month period) (357, 358) and is clearly associated with contraceptive failure (359–363). In the great majority of studies published so far, monitoring of ovarian function is performed infrequently (screening intervals usually varies between twice weekly or once every month), and hormone assays and ultrasound for the assessment of follicle growth are rarely combined. However, substantial ovarian activity is uniformly reported when women use steroid regimens that are presently on the market. The concept arises that FSH levels rise during the pill-free interval above the 'threshold' for follicle recruitment (Fig. 6, *bottom panel*), and that follicle growth around the stage of dominant follicle selection is usually arrested after initiation of the next pill cycle. Improved understanding of ovarian activity during oral contraceptive medication may help to design novel strategies for steroid contraception.

B. Ovarian suppression during steroid contraception

1. *Significance of initiation of pill intake and duration of treatment.* According to some authors previous steroid medication does not seem to influence suppressive activity of combined steroid contraceptives (364, 365). Starting with the first pill cycle on a fixed day of the week, as initially advised, may postpone initiation of pill intake until day 6 of the normal menstrual cycle. If dominant follicle selection has already occurred (which may certainly be the case on cycle day 6, as discussed in *Section II.E.3*), progression of follicle growth may occur after pill intake (366). A careful study involving 58 sponta-

neous cycles and 22 first oral contraceptive pill cycles convincingly showed that a far greater suppression of ovarian activity was achieved by starting on day 1 as compared with day 5. As much as 60% ($n = 11$) of day 5 starters reached dominant follicle development (367). Hence, it should be advised that the first treatment cycle begin on cycle day 1 or 2 (368). Some investigators observed a trend toward a minor increase in ovarian activity during extended pill use (369). In contrast, gonadotropin suppression early in the pill cycle was reported to be similar over a 9-month treatment period (370). Few detailed studies have been published regarding the effect of previous use of oral contraceptives on follicular phase characteristics after stopping pill intake.

2. Comparison of different steroid doses, compounds, and regimens. Greater ovarian suppression was observed when pills containing 50 vs. 35 μg EE were compared (351, 371). Moreover, suppression of FSH was shown to be less pronounced in monophasics containing 20 $\mu\text{g}/\text{day}$ EE as compared with 30 $\mu\text{g}/\text{day}$ EE (372). Consequently, the margin for error is reduced if doses of daily steroid intake are diminished. According to some investigators, low-dose triphasic pills appear to be slightly less effective in ovarian inhibition as compared with monophasic preparations (373–375). Little difference, if any, was noticed when ovarian activity during intake of various progestational agents was compared (369, 374, 376, 377).

In contrast, follicle growth up to the preovulatory stage (378) and sonographic or endocrine evidence of ovulation have been reported in 30–60% of women in whom continued progestin-only pills or implants are used (379–384). Studies employing daily blood sampling showed major differences in luteal phase characteristics, but all with substantial follicular phase E_2 production (382) (Fig. 13). It has become

apparent that the individual response to progestin-only medication is extremely variable. Substantial changes in serum E_2 levels coincide with follicle growth in these women. Surprisingly, some women exhibit extended periods with supraphysiological E_2 levels, whereas other women show complete ovarian suppression with serum E_2 levels in the postmenopausal range. Moreover, extended use of progestin-only implants may coincide with reduced suppression of ovarian activity (385). As opposed to combined contraceptives, positive feedback effects of endogenous E_2 may override negative feedback actions of exogenous progestins alone. However, the LH surge is usually blunted and progesterone may merely be secreted by luteinized follicles. Because pregnancy rates remain extremely low, it appears that other mechanisms such as luteal phase deficiency, and progestin effects directly on cervical mucus quality, endometrial and possibly tubal function prevent conception in these cases. Irregular bleeding is the major drawback, which prevents large-scale use of this contraceptive method (386). A connection between irregular bleeding and residual ovarian activity has been described (383). A discontinued progestin regimen combined with melatonin, the pineal hormone involved in seasonal breeding in some animal species, has also been explored as a potential contraceptive agent (387). However, contraceptive efficacy of this regimen has never been demonstrated.

3. Pill-free interval and pill omission. The pill-free interval may impair contraceptive efficacy (355). However, potential benefits are the reassurance of monthly withdrawal bleeding, a lower monthly quantity of synthetic steroids, and improvement of metabolic changes during the pill-free week. A considerable rise in serum FSH levels and subsequent ovarian activity is usually observed during the pill-free interval and




FIG. 13. Serum hormone (LH, FSH, estradiol, and progesterone) levels in regularly cycling controls ($n = 12$; $\circ-\circ$) and depot progestagen (Norplant) users presenting with luteal activity ($n = 12$; $\bullet-\bullet$), minimal luteal activity ($n = 5$; $\blacktriangle-\blacktriangle$), or no luteal activity ($n = 14$; $\triangle-\triangle$). [From Faundes A, Brache V, Tejada AS, Cochon L, Alvarez-Sanchez F. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants. *Fertil Steril* 1991; 56:27–31. Reproduced with permission of the publisher, The American Society for Reproductive Medicine (formerly The American Fertility Society).]

the first week thereafter (388–390). At the end of the pill-free week, integrated gonadotropin concentrations and pulse patterns (350) were indistinguishable from those of controls, whereas E_2 concentrations were significantly lower (389, 391). Ultrasound scanning on day 7 of the pill-free interval in 120 volunteers showed follicles more than 10 mm diameter in 23% of women (392). Frequent monitoring in 31 females showed that maximum E_2 concentrations usually occur on day 1 of the pill cycle, and maximum follicle diameter (median 10–12 mm) was observed on day 3 (369). These studies confirm indeed that maximum ovarian activity is present shortly after the pill-free week.

Studies from our own group (393) (A. M. van Heusden and B. C. J. M. Fauser; unpublished observations), applying daily blood sampling and TVS during the pill-free period in 36 low-dose, combined oral contraceptive pill users (containing daily doses of 50 μ g EE and 2.5 mg lynestrenol) confirm that maximum FSH levels at the end of the pill-free interval are similar to early follicular phase maximum levels in the natural cycle [7.4 (4.1–12.8) vs. 6.6 (4.4–11.2) IU/liter]. Moreover, maximum E_2 levels during or shortly after the pill-free week are also comparable to E_2 levels at the day of dominant follicle selection in the normal cycle; 36 (8–85) vs. 47 (25–97) pg/ml. Twenty five percent of women exhibit follicles ≥ 10 mm. See also Fig. 14, and Tables 1 and 7.

It has appeared that the omission of one or more pills frequently occurs among oral contraceptive pill users. When transient interruption of several days of pill intake occurs in the middle of the pill cycle after a period of at least 7 days of uninterrupted use, the duration of reduced suppression of FSH release is not sufficient to allow for substantial reactivation of ovarian function (394). This observation, however, is not confirmed in all studies (390, 395), and contraceptive efficacy may still be compromised (396). In addition, the incidence of spotting was reported to be significantly increased in subjects omitting the pill in the second half of the pill cycle (394, 397). Ovulation and subsequent conception may take place when pill omission occurs around the pill-free interval. Various studies have been undertaken to investigate ovarian activity after the deliberate and transient interruption of pill intake during different phases of the pill cycle (398). Pill omission around the pill-free interval — effectively extending the period of pituitary recovery — results in more pronounced ovarian activity with continued growth of follicles (399).

C. Follicle growth dynamics during contraceptive regimens

Between 23 and 90% of combined oral contraceptive pill users have been reported to exhibit follicles beyond 10 mm diameter during frequent pelvic ultrasound (367, 369, 375, 388, 392, 400–402) (Fig. 15 and Table 8). Less information is available regarding accompanying serum E_2 levels. In about 25% of cycles, E_2 levels were reported to be above early follicular phase concentrations in control cycles (400). This should be considered stages beyond dominant follicle selection, based on findings of follicle size and concomitant steroid production during the spontaneous menstrual cycle (163, 206) (see also Section II.E.3). Follicles were reported to grow until a size of 12 mm in 35% of 75 treatment cycles.




FIG. 14. Follicular phase serum FSH levels (upper panel), maximum follicle diameter (mm) (middle panel), and E_2 levels (bottom panel) (mean and 95% confidence intervals) according to day of the pill-free interval in 36 women using low-dose combined steroid contraceptive pills. Ultrasound scans and blood sampling were performed daily (A. M. van Heusden and B. C. J. M. Fauser). The dotted line in the middle panel indicates mean size of all observed follicles.

Follicles greater than 13 mm were rarely observed in some reports (388) but were seen frequently in other publications (400, 403). Preovulatory follicles (≥ 18 mm) were observed in as much as 30% of cycles in a study involving 400 pill cycles (400). In a recent well designed study, follicles between 10 and 18 mm were observed in 30–50% of volunteers during treatment days 1–5 (403). Attempts to classify ovarian activity during oral contraceptive medication (404) have not gained wide acceptance. A biological rationale and appropriate reference values were lacking.

Once contraceptive pill intake is reinitiated, subsequent follicle maturation is usually arrested and follicles disappear (369). An elegant study was undertaken to monitor the ca-

TABLE 7. Endocrine and sonographic characteristics of the pill-free week in women using combined steroid contraceptive pills (n = 36)

	Median (range)
Day 1 of the pill-free week	
FSH concentration (IU/liter)	0.3 (0.1–7.8)
E ₂ concentration (pg/ml)	8 (3–25)
Follicle diameter (mm)	5 (3–20)
Day 8 (first day of next pill cycle)	
FSH concentration (IU/liter)	5.9 (3.5–12.3)
E ₂ concentration (pg/ml)	33 (5–83)
Maximum follicle diameter (mm)	8 (4–19)
Maximum FSH	
Concentration (IU/liter)	7.4 (4.1–12.8)
Day	7 (2–9)
Maximum E ₂	
Concentration (pg/ml)	36 (8–85)
Day	8 (6–10)
Largest follicle	
Diameter (mm)	9 (6–21)
Day	9 (5–10)
Dominance (% of women with follicles ≥ 10 mm)	
	25

Medication involved low-dose combined steroid contraceptive pills. Sampling was performed daily for 10 days, starting on the first day of the pill-free week. [Derived from Ref. 393 and A. M. van Heusden and B. C. J. M. Fauser (unpublished observations).]




FIG. 15. Maximum diameter of the largest follicle (mean and SD) during six treatment cycles using various contraceptive regimens, such as multiphasic pills, higher-dose monophasic pills, lower-dose monophasic pills, and nonsteroidal contraception. [Reprinted with permission from The American College of Obstetricians and Gynecologists (*Obstetrics and Gynecology*, 1994, 83:29–34).]

capacity of these follicles to ovulate. Follicles were allowed to develop until their diameter reached 12 mm by extending the pill-free period by 3–7 days (405) (Fig. 16). Despite the initiation of contraceptive medication, most follicles continued to grow and responded to hCG administration by both rupture and luteinization. Hence, this study strongly suggests that follicles that reach a more advanced state of maturation during steroid contraceptive medication retain the capacity for continued growth and ovulation despite decreasing FSH levels. It has been suggested by some authors that the growth rate of the dominant follicle is slower as compared with normal conditions, whereas circulating E₂ levels remain normal according to follicle size (367). Incidentally, escape ovu-

lations have been observed during combined steroid contraception (400). However, this event rarely occurs with regular pill intake, because the endogenous LH surge does not occur even if follicles have reached full maturation (367, 388).

The occurrence of ovarian cysts in some patients may be related to preovulatory follicle development without subsequent ovulation. As described before, this is frequently observed during progestin-only medication. The occurrence of functional ovarian cysts may be prevented more effectively by monophasic (especially high-dose) pills as compared with triphasic combinations (406).

D. Alternative strategies for contraceptive development

Extensive breakthrough bleeding may occur in women using continued progestin-only contraception. This may be caused by endometrial atrophy, but may also be related to considerable individual variability in ovarian activity and subsequent estrogen production. Extended periods of E₂ levels above the normal range for regularly cycling women may also induce an increased risk for future health hazards.

During the pill-free interval FSH levels are reached that are in the same order of magnitude as during the early follicular phase of the normal menstrual cycle. Consequently, follicle recruitment takes place and dominant follicle selection occurs in a significant proportion of women using combined steroid contraception. The reduced need of the dominant follicle for continued support by high levels of FSH (see Section II.E) suggests that ongoing development until full maturation may occur despite decremental FSH serum levels due to the start of pill intake of the next cycle. Substantial follicle development has indeed been confirmed in contraceptive pill users. Unfortunately, uniform criteria to categorize ovarian activity during various steroid regimens have not been accepted, which renders it difficult to compare different studies. It has been documented that ovarian activity during similar contraceptive regimens vary widely (399, 407, 408). This observation may have important clinical implications because the magnitude of ovarian activity may be related to contraceptive efficacy, breakthrough bleeding, and ovarian cyst development. Tolerance for pill omission — especially early or late in the pill cycle, which effectively extends the pill-free interval — or for reduced availability of steroids (due to individual differences in steroid metabolism, drug interaction, diarrhea, or vomiting) has decreased substantially with the presently available low-dose contraceptives (355). Efficacy may be severely compromised in these cases. It should also be realized that tolerance for pill omission will be dependent on the developmental stage of follicles when pills are missed. On the basis of the above mentioned considerations, future strategies for further development of steroid contraceptive regimens (see also Table 9) may include:

1. The monthly 7-day pill-free interval has become critical for efficacy (especially tolerance for pill omission) of currently used low-dose contraceptives. A 7-day pill-free interval was arbitrarily chosen for reassurance to mimic the natural cycle, when the pill was introduced in the early 1960s. Doses may be diminished further or tolerance for error of

TABLE 8. Overview of studies focusing on residual ovarian activity during combined steroid contraceptive regimens

Author, published year (Ref.)	Study setting	Ultrasound observations (% of women with follicles ≥ 10 mm)	Endocrine observations
van der Vange, 1986 (400)	7 low-dose combinations (n = 70)	29% (17% follicles ≥ 18 mm)	27% serum E ₂ levels > 75 pg/ml
Tayob <i>et al.</i> , 1990 (392)	Multiple combinations (n = 120)	23%	
Thomas and Vankrieken, 1990 (388)	30 μ g EE + 75 mg GSD (n = 25)	up to 44%	No luteal activity
Grimes <i>et al.</i> , 1994 (375)	35 μ g EE + NET mono-, triphasic (n = 45)	Between 29–50% (up to 13% ovarian cysts)	Up to 5% ovulation
Broome <i>et al.</i> , 1995 (378)	Triphasic; 30–40 μ g EE + LNG (n = 17)	24%	
van der Does <i>et al.</i> , 1996 (369)	Triphasic; 30–40 μ g EE + LNG or DSG (n = 31)	Up to 73% (up to 60% follicles > 15 mm)	1 ovulation, 1 LUF

EE, Ethinyl estradiol; GSD, gestodene; NET, norethisterone; LNG, levonorgestrel; DSG, desogestrel; LUF, luteinized unruptured follicle.




FIG. 16. The ovulatory potential of follicles was studied in 10 women by extending the pill-free interval (up to 7 additional days) allowing follicles to grow until 12 mm in diameter (○). hCG was administered when follicles attained a diameter of 18 mm (left panel). Serum estradiol and progesterone levels (median and range) on the day of hCG administration and 7 or 9 days later (right panel) suggest normal ovulatory potential. [From Killick SR Ovarian follicles during oral contraceptive cycles: their potential for ovulation. *Fertil Steril* 1989; 52:580–582. Reproduced with permission of the publisher, the American Society for Reproductive Medicine (formerly The American Fertility Society).]

tablet taking may improve if the pill-free interval is reduced in length (e.g. to 5 days), or reduced in frequency (e.g. once every 2–3 months instead of monthly). Indeed, it has been shown that withdrawal bleeding can be extended to once every 2 (409, 410) or 3 (411) months in the majority of women, and it was stated (411) that ‘many of the women who vol-

unteered liked using a contraceptive that also reduced the frequency of their menstrual periods.’

2. Steroid dose regimens of combined contraceptives may also be altered. It is uncertain whether there is anything to be gained by the presently available triphasic regimens. The most pronounced suppression of FSH is needed early in the

TABLE 9. Hypothetical options for reduction of residual ovarian activity and, therefore, improved efficacy of combined steroid contraceptive pills

1. Reduction of the duration of the 7 day pill-free interval or reduction of the frequency of the pill-free week
2. Alternative dose regimens, with higher doses of steroids early in the pill cycle
3. Continued estrogen intake during the pill-free interval
4. Assessment of individual ovarian sensitivity for FSH stimulation (so-called FSH threshold), possibly at the end of the pill-free interval, and adjustment of steroid doses on an individual basis

pill cycle, and therefore higher doses of steroids may need to be applied during the first days rather than later in the pill cycle. Testing of a decremental steroid dose regimen should perhaps be considered, although it is uncertain whether bleeding control would be compromised.

3. Low doses of estrogens could be continued during the pill-free interval without interference with bleeding patterns, as has been shown for postmenopausal hormone replacement therapy. This may reduce the rise in FSH and subsequent recovery of ovarian activity during the pill-free week.

Altogether, the above mentioned attempts are aiming at reducing the frequency, magnitude, or duration of pituitary recovery and subsequent initiation of gonadotropin-dependent follicle growth.

4. A completely different strategy focuses on the major individual variability in residual ovarian activity during similar steroid contraceptive medication. A 2.5-fold difference in maximum circulating FSH concentrations has been observed by our group in a carefully selected group of volunteers with normal ovarian function (163). This seems to indicate that a major individual variability in ovarian sensitivity for FSH stimulation exists. The observed variability in ovarian suppression during oral contraceptive medication may be related to a differences in ovarian 'FSH threshold,' rather than differences in sensitivity of the hypothalamic-pituitary unit for negative steroid feedback. It may be possible to predict which subject will be prone to escape ovulation and reduced contraceptive efficacy, by the individual assessment of hormone levels and follicle dynamics during contraceptive medication, particularly at the end of the pill-free interval. This approach may lead to better tailoring of dose and type of steroid regimens according to individual needs, providing an extended strategy for 'designer' (412) contraceptive pills.

V. Conclusions and Future Directions

Growth of follicles from the resting primordial stage until the preovulatory phase takes several months. Only the last 2 weeks of this long trajectory are dependent on stimulation by gonadotropins and can therefore be manipulated in the human at present. If maturing antral follicles achieve a distinct stage of development they are programmed to die. Only if serum FSH levels surpass a threshold (which is different from one individual to the other) these follicles are rescued from atresia, *i.e.* gain gonadotropin dependence, and continue their development. Under normal conditions, increased FSH levels above the threshold occur during the luteo-follicular transition. Subsequent decremental FSH con-

centrations during the follicular phase are crucial for single dominant follicle selection.

Continued growth of the dominant follicle despite reduced late follicular phase stimulation by FSH suggests increased sensitivity. Local autocrine up-regulation by increased intraovarian E_2 production has been implemented as the underlying cause of this reduced need for FSH stimulation. However, increased E_2 levels are only associated with follicle diameter exceeding 10 mm. Moreover, from this size onward a dominant follicle can be visualized by TVS, suggesting that only dominant follicle development is associated with increased aromatase enzyme activity in granulosa cells. Several lines of evidence have convincingly demonstrated that increased intrafollicular E_2 biosynthesis is not mandatory for continued follicle growth up to the preovulatory stage. These observations strongly, although indirectly, suggest that intraovarian modification of FSH takes place through other factors, and that as yet unidentified factors drive growth of the dominant follicle. The concept of a reduced need for stimulation by FSH of the dominant follicle bears significance for both gonadotropin induction of ovulation (*i.e.* stimulation of ovarian function by exogenous FSH in anovulatory infertile patients) and residual ovarian activity during low-dose steroid contraceptive regimens.

Gonadotropins have been used worldwide for over three decades for the treatment of anovulatory patients. Treatment is successful, although complication rates related to multiple follicle development remain high. Over the years, tools to monitor ovarian response have improved considerably and new drugs have been introduced. In addition, treatment regimens have been modified by lowering the doses administered. However, information regarding patient diagnosis and precise follow-up of the interplay between circulating FSH concentrations and follicle growth dynamics remains scarce. It may be possible to further improve the balance between success and complications by more rigidly applying physiological concepts. Endocrine profile and follicle growth during step-down FSH treatment compare almost precisely to changes observed during the follicular phase of the normal menstrual cycle.

Presently available, low-dose steroid contraception is characterized by extensive residual ovarian activity and reduced tolerance for omission of pill intake. The endocrine profile and follicle growth dynamics in pill users during and shortly after the pill-free interval are compared with the normal menstrual cycle. Alternative strategies for contraceptive development to improve the safety margin can be postulated on the basis of this comparison.

Acknowledgments

The authors would like to express their gratitude to Prof. Aaron J. W. Hsueh, Prof. Philippe Bouchard, and Dr. Herjan J. T. Coelingh Bennink for critically reviewing the manuscript. Fellows previously working in our unit whose work has been discussed in this review (Thierry D. Pache, Dick C. Schoot, Evert P. van Santbrink, Thierry J. van Dessel, and Jits Schipper) are gratefully acknowledged.

References

1. Block E 1951 Quantitative morphological investigations of the follicular system in women. *Acta Endocrinol (Copenh)* 8:33-54

2. **Simkins CS** 1952 Development of the human ovary from birth to sexual maturity. *Am J Anat* 51:465-493
3. **Baker TC** 1963 A quantitative and cytological study of germ cells in human ovaries. *Proc R Soc Lond [Biol]* 158:417-433
4. **Desa DJ** 1975 Follicular ovarian cysts in stillbirths and neonates. *Arch Dis Child* 50:45-50
5. **Richardson SJ, Senikas V, Nelson JF** 1987 Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion. *J Clin Endocrinol Metab* 65:1231-1237
6. **Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF** 1992 Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. *Hum Reprod* 7:1342-1346
7. **Gougeon A** 1993 Dynamics of human follicle growth. A morphologic perspective. In: Adashi EY, Leung PCK (eds) *The Ovary*. Raven Press, New York, pp 21-39
8. **Faddy MJ, Gosden RG** 1995 A mathematical model of follicle dynamics in the human ovary. *Hum Reprod* 10:770-775
9. **Hirshfield AN** 1994 Relationship between the supply of primordial follicles and the onset of follicular growth in rats. *Biol Reprod* 50:421-428
10. **Gougeon A** 1986 Dynamics of follicular growth in the human: a model from preliminary results. *Hum Reprod* 1:81-87
11. **Gougeon A, Ecochard R, Thalabard JC** 1994 Age-related changes of the population of human ovarian follicles: increase in the disappearance rate of non-growing and early-growing follicles in aging women. *Biol Reprod* 50:653-663
12. **Gougeon A** 1996 Regulation of ovarian follicular development in primates: facts and hypothesis. *Endocr Rev* 17:121-155
13. **Gougeon A, Chainy GB** 1987 Morphometric studies of small follicles in ovaries of women at different ages. *J Reprod Fertil* 81:433-442
14. **Scaramuzzi RJ, Adams NR, Baird DT, Campbell BK, Downing JA, Findlay JK, Henderson KM, Martin GB, McNatty KP, McNeilly AS, Tsonis CG** 1993 A model for follicle selection. *Reprod Fertil Dev* 5:459-478
15. **Channing CP, Kammerman S** 1973 Characteristics of gonadotropin receptors of porcine granulosa cells during follicle maturation. *Endocrinology* 92:531-540
16. **Roy SK, Wang SC, Greenwald GS** 1987 Radioreceptor and autoradiographic analysis of FSH, hCG and prolactin binding sites in primary to antral hamster follicles during the periovulatory period. *J Reprod Fertil* 79:307-313
17. **Gougeon A** 1982 Rate of follicular growth in the human ovary. In: Rolland R, van Hall EV, Hillier SG, McNatty KP, Schoemaker J (eds) *Follicular Maturation and Ovulation*. Elsevier, Excerpta Medica, Amsterdam, pp 155-163
18. **Schwartzman RA, Cidlowski JA** 1993 Apoptosis: The biochemistry and molecular biology of programmed cell death. *Endocr Rev* 14:133-151
19. **Tilly JL, Tilly KI** 1995 Inhibitors of oxidative stress mimic the ability of follicle-stimulating hormone to suppress apoptosis in cultures rat ovarian cells. *Endocrinology* 136:242-252
20. **Billig H, Furuta I, Hsueh AJW** 1993 Estrogens inhibit and androgens enhance ovarian granulosa cell apoptosis. *Endocrinology* 133:2204-2212
21. **Hsueh AJW, Billig H, Tsafiriri A** 1994 Ovarian follicle atresia: a hormonally controlled apoptotic process. *Endocr Rev* 15:707-724
22. **Billig H, Furuta I, Hsueh AJ** 1994 Gonadotropin-releasing hormone directly induces apoptotic cell death in the rat ovary: biochemical and *in situ* detection of deoxyribonucleic acid fragmentation in granulosa cells. *Endocrinology* 134:245-252
23. **Chun SY, Billig H, Tilly JL, Furuta I, Tsafiriri A, Hsueh AJ** 1994 Gonadotropin suppression of apoptosis in cultured preovulatory follicles: mediatory role of endogenous insulin-like growth factor I. *Endocrinology* 135:1845-1853
24. **Peters H, Himelstein-Braw R, Faber M** 1976 The normal development of the ovary in childhood. *Acta Endocrinol (Copenh)* 82:617-630
25. **Smith PE, Engle ET** 1927 Experimental evidence regarding the role of the anterior pituitary in the development and regulation of the genital system. *Am J Anat* 40:159-217
26. **Hisaw FL** 1947 Development of the Graafian follicle and ovulation. *Physiol Rev* 27:95-119
27. **Baker TC, Scrimgeour JB** 1980 Development of the gonad in normal and anencephalic human fetuses. *J Reprod Fertil* 60:193-199
28. **Greenwald GS, Roy SK** 1994 Follicular development and its control. In: Knobil E, Neill JD (eds) *The Physiology of Reproduction*. Raven Press, New York, pp 629-724
29. **Richardson SJ, Nelson JF** 1990 Follicular depletion during the menopausal transition. *Ann NY Acad Sci* 592:13-20
30. **Polhemus DW** 1953 Ovarian maturation and cyst formation in children. *Pediatrics* 11:588-594
31. **Sauramo H** 1954 Histology and function of the ovary from the embryonic period to the fertile age. *Acta Obstet Gynecol Scand* 33[Suppl 2]:1-25
32. **Valdes-Dapena MA** 1967 The normal ovary of childhood. *Ann NY Acad Sci* 34:597-613
33. **Lintern-Moore S, Peters H, Moore GP, Faber M** 1974 Follicular development in the infant human ovary. *J Reprod Fertil* 39:53-64
34. **Nelson WW, Forks G, Greene RR** 1958 Some observations on the histology of the human ovary during pregnancy. *Am J Obstet Gynecol* 76:66-90
35. **Govan AD** 1970 Ovarian follicular activity in late pregnancy. *J Endocrinol* 48:235-241
36. **Dekel N, David MP, Yedwab GA, Kraicer PF** 1977 Follicular development during late human pregnancy. *Int J Fertil* 22:24-29
37. **Westergaard L, McNatty KP, Christensen IJ** 1985 Steroid concentrations in fluid from human ovarian antral follicles during pregnancy. *J Endocrinol* 107:133-136
38. **Schoot DC, Harlin J, Shoham Z, Mannaerts BMJL, Lahlou N, Bouchard P, Coelingh Bennink HJT, Fauser BCJM** 1994 Recombinant human follicle-stimulating hormone and ovarian response in gonadotrophin-deficient women. *Hum Reprod* 9:1237-1242
39. **Halpin DM, Jones A, Fink G, Charlton HM** 1986 Postnatal ovarian follicle development in hypogonadal (hpg) and normal mice and associated changes in the hypothalamic-pituitary ovarian axis. *J Reprod Fertil* 77:287-296
40. **Richards JS, Jahnsen T, Hedin L, Lifka J, Ratoosh S, Durica JM, Goldring NB** 1987 Ovarian follicular development: from physiology to molecular biology. *Recent Prog Horm Res* 43:231-276
41. **Richards JS, Hedin L** 1988 Molecular aspects of hormone action in ovarian follicular development, ovulation, and luteinization. *Annu Rev Physiol* 50:441-463
42. **Gulyas BJ, Hodgen GD, Tullner WW, Ross GT** 1977 Effects of fetal or maternal hypophysectomy on endocrine organs and body weight in infant rhesus monkeys (*Macaca mulatta*): with particular reference on oogenesis. *Biol Reprod* 16:216-227
43. **Goldenberg RL, Powell RD, Rosen SL, Marshall JR, Ross GT** 1976 Ovarian morphology in women with anosmia and hypogonadotropic hypogonadism. *Am J Obstet Gynecol* 126:91-94
44. **McNatty KP, Smith P, Hudson NL, Heath DA, Lun S, O WS** 1992 Follicular development and steroidogenesis. In: Sjoberg NO, Hamberger L, Janson PO, Owman C, Coelingh-Bennink HJ (eds) *Local Regulation of Ovarian Function*. Parthenon Publishing, Casterton Hall, UK, pp 21-38
45. **Montgomery GW, McNatty KP, Davis GH** 1992 Physiology and molecular genetics of mutations that increase ovulation rate in sheep. *Endocr Rev* 13:309-328
46. **Martin NG, Olsen ME, Theile H, El Beaini JL, Handelsman D, Bhatnagar AS** 1984 Pituitary-ovarian function in mothers who have had two sets of dizygotic twins. *Fertil Steril* 41:878-880
47. **Martin NG, Robertson DM, Chenevix-Trench G, de Kretser DM, Osborne J, Burger HG** 1991 Elevation of follicular phase inhibin and luteinizing hormone levels in mothers of dizygotic twins suggests nonovarian control of human multiple ovulation. *Fertil Steril* 56:469-474
48. **Gilfillan CP, Robertson DM, Burger HG, Leoni MA, Hurley VA, Martin NG** 1996 The control of ovulation in mothers of dizygotic twins. *J Clin Endocrinol Metab* 81:1557-1562
49. **Krasnow J** 1991 Advances in understanding ovarian physiology: Regulation of steroidogenic enzymes in ovarian follicular differentiation. *Semin Reprod Endocrinol* 9:283-302
50. **Strauss JF, Miller WL** 1991 Molecular basis of ovarian steroid synthesis. In: Hillier SG (ed) *Ovarian Endocrinology*. Blackwell, Oxford, U.K., pp 25-72
51. **Takayama K, Sasano H, Fukaya T, Morohashi K, Suzuki T,**

- Tamura M, Costa MJ, Yajima A 1995 Immunohistochemical localization of Ad4-binding protein with correlation to steroidogenic enzyme expression in cycling human ovaries and sex cord stromal tumors. *J Clin Endocrinol Metab* 80:2815–2821
52. Lin D, Sugawara T, Strauss III JF, Clark BJ, Stocco DM, Saenger P, Rogol A, Miller WL 1995 Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. *Science* 267:1828–1831
 53. Fauser BCJM, Hsueh AJW 1995 Genetic basis of human reproductive endocrine disorders. *Hum Reprod* 10:826–846
 54. Makris A, Ryan KJ 1977 Aromatase activity of isolated and recombined hamster granulosa cells and theca. *Steroids* 29:65–72
 55. Tsang BK, Moon YS, Simpson CW, Armstrong DT 1979 Androgen biosynthesis in human ovarian follicles: cellular source, gonadotropin control, and adenosine 3,5-monophosphate mediation. *J Clin Endocrinol Metab* 48:153–158
 56. Tsang BK, Armstrong DT, Whitfield JF 1980 Steroid biosynthesis by isolated human ovarian follicular cells *in vitro*. *J Clin Endocrinol Metab* 51:1407–1411
 57. Brailly S, Gougeon A, Milgrom E, Bomsel-Helmreich O, Papiernik E 1981 Androgens and progestins in the human ovarian follicle: differences in the evolution of preovulatory, healthy non-ovulatory, and atretic follicles. *J Clin Endocrinol Metab* 53:128–134
 58. Moon YS, Tsang BK, Simpson C, Armstrong DT 1978 17β -estradiol biosynthesis in cultured granulosa cells of human ovarian follicles: stimulation by FSH. *J Clin Endocrinol Metab* 47:263–267
 59. Erickson GF, Hsueh AJW, Quigley ME, Rebar RW, Yen SSC 1979 Functional studies of aromatase activity in human granulosa cells from normal and polycystic ovaries. *J Clin Endocrinol Metab* 49:514–519
 60. Hillier SG, Reichert LE, van Hall EV 1981 Control of preovulatory follicular estrogen biosynthesis in the human ovary. *J Clin Endocrinol Metab* 52:847–856
 61. Voutilainen R, Tapanainen J, Chung BC, Matteson KJ, Miller WL 1986 Hormonal regulation of P450 scc (20, 22-desmolase) and P450c17 (17 α -hydroxylase/17, 20-lyase) in cultured human granulosa cells. *J Clin Endocrinol Metab* 63:202–207
 62. Sasano H, Okamoto M, Mason JI, Simpson ER, Mendelson CR, Sasano N, Silverberg SG 1989 Immunolocalization of aromatase, 17α -hydroxylase and side-chain-cleavage cytochromes P-450 in the human ovary. *J Reprod Fertil* 85:163–169
 63. Doody KJ, Lorence MC, Mason JI, Simpson ER 1990 Expression of mRNA species encoding steroidogenic enzymes in human follicles and corpora lutea throughout the menstrual cycle. *J Clin Endocrinol Metab* 70:1041–1045
 64. McAllister JM, Mason JI, Byrd W, Trant JM, Waterman MR, Simpson ER 1990 Proliferating human granulosa-lutein cells in long term monolayer culture: expression of aromatase, cholesterol side-chain cleavage, and 3 beta-hydroxysteroid dehydrogenase. *J Clin Endocrinol Metab* 71:26–33
 65. Simpson ER, McAllister JM, Lauber M, Demeter M, Waterman MR 1992 Regulation of expression of genes that encode steroidogenic enzymes in the ovary. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR (eds) *Polycystic Ovary Syndrome*. Blackwell Scientific Publications, Boston, pp 71–77
 66. Suzuki T, Sasano H, Tamura M, Aoki H, Fukaya T, Yajima A, Nagura H, Mason JI 1993 Temporal and spatial localization of steroidogenic enzymes in premenopausal human ovaries: *in situ* hybridization and immunohistochemical study. *Mol Cell Endocrinol* 97:135–143
 67. Inkster SE, Brodie AMH 1991 Expression of aromatase cytochrome P-450 in premenopausal and postmenopausal human ovaries: an immunocytochemical study. *J Clin Endocrinol Metab* 73:717–726
 68. Hillier SG, van der Boogaard AMJ, Reichert Jr LE, van Hall EV 1980 Intraovarian sex steroid hormone interactions and the regulation of follicular maturation: aromatization of androgens by human granulosa cells *in vitro*. *J Clin Endocrinol Metab* 50:640–647
 69. Steinkampf MP, Mendelson CR, Simpson ER 1987 Regulation by follicle-stimulating hormone of the synthesis of aromatase cytochrome P-450 in human granulosa cells. *Mol Endocrinol* 1:465–471
 70. Richards JS 1993 Gonadotropin-regulated gene expression in the ovary. In: Adashi EY, Leung PCK (eds) *The Ovary*. Raven Press, New York, pp 93–111
 71. Erickson GF, Magoffin DA, Dyer CA, Hofeditz C 1985 The ovarian androgen producing cells: a review of structure/function relationships. *Endocr Rev* 6:371–399
 72. Magoffin DA 1991 Regulation of differentiated functions in ovarian theca cells. *Semin Reprod Endocrinol* 9:321–331
 73. McNatty KP, Baird DT, Bolton A, Chambers P, Corker CS, McLean H 1976 Concentration of oestrogens and androgens in human ovarian venous plasma and follicular fluid throughout the menstrual cycle. *J Endocrinol* 71:77–85
 74. Pache TD, Hop WC, De Jong FH, Leertveld RA, van Geldorp H, Van de Kamp TM, Gooren LJ, Fauser BC 1992 17β -Oestradiol, androstenedione and inhibin levels in fluid from individual follicles of normal and polycystic ovaries, and in ovaries from androgen treated female to male transsexuals. *Clin Endocrinol (Oxf)* 36:565–571
 75. van Dessel HJHM, Schipper I, Pache TD, van Geldorp H, De Jong FH, Hop WCJ, Fauser BCJM 1996 Normal human follicle development: an evaluation of correlations with oestradiol, androstenedione and progesterone levels in individual follicles. *Clin Endocrinol (Oxf)* 44:191–198
 76. Westergaard L, Christensen IJ, McNatty KP 1986 Steroid levels in ovarian follicular fluid related to follicle size and health status during the normal menstrual cycle in women. *Hum Reprod* 1:227–232
 77. Bomsel-Helmreich O, Gougeon A, Thebault A, Saltarelli D, Milgrom E, Frydman R, Papiernik E 1979 Healthy and atretic human follicles in the preovulatory phase: differences in evolution of follicular morphology and steroid content of follicular fluid. *J Clin Endocrinol Metab* 48:686–694
 78. Fevold HL 1941 Synergism of follicle stimulating and luteinising hormone in producing oestrogen secretion. *J Clin Endocrinol Metab* 21:33–36
 79. Greep RO, van Dyke HB, Chow BF 1942 Gonadotropins of the swine pituitary. I. Various biological effects of purified thylenestrin (FSH) and pure metakentrin (ICSH). *Endocrinology* 30:635–649
 80. Short RV 1962 Steroids in the follicular fluid and the corpus luteum of the mare. A 'two cell type' theory of ovarian steroid synthesis. *J Endocrinol* 24:59–63
 81. Eshkol A, Lunenfeld B 1967 Purification and separation of follicle stimulating hormone (FSH) and luteinizing hormone (LH) from human menopausal gonadotrophin (HMG). 3. Effects of a biologically apparently pure FSH preparation on ovaries and uteri of intact, immature mice. *Acta Endocrinol (Copenh)* 54:91–95
 82. Berger MJ, Taymor ML 1971 The role of luteinizing hormone in human follicular maturation and function. *Am J Obstet Gynecol* 111:708–712
 83. Sanyal MK, Berger MJ, Thompson IE, Taymor ML, Horne HW 1974 Development of Graafian follicles in adult human ovary. I. Correlation of estrogen and progesterone concentration in antral fluid with growth of follicles. *J Clin Endocrinol Metab* 38:828–835
 84. McNatty KP, Hunter WM, McNeilly AS, Sawers RS 1975 Changes in the concentration of pituitary and steroid hormones in the follicular fluid of human graafian follicles throughout the menstrual cycle. *J Endocrinol* 64:555–571
 85. Fowlers RE, Chan ST, Edwards RG, Walters DE, Steptoe PC 1977 Steroidogenesis in human follicles approaching ovulation as judged from assays of follicle fluid. *J Endocrinol* 72:259–271
 86. Seibel MM, Smith D, Dlugi AM, Levesque L 1989 Periovarian follicular fluid hormone levels in spontaneous human cycles. *J Clin Endocrinol Metab* 68:1073–1077
 87. Schoot BC, Coelingh Bennink HJ, Mannaerts BM, Lamberts SW, Bouchard P, Fauser BC 1992 Human recombinant follicle-stimulating hormone induces growth of preovulatory follicles without concomitant increase in androgen and estrogen biosynthesis in a woman with isolated gonadotropin deficiency. *J Clin Endocrinol Metab* 74:1471–1473
 88. Baird DT, Fraser IS 1975 Concentration of oestrone and oestradiol in follicular fluid and ovarian venous blood of women. *Clin Endocrinol (Oxf)* 4:259–266
 89. Chikazawa K, Araki S, Tamada T 1986 Morphological and endocrinological studies on follicular development during the human menstrual cycle. *J Clin Endocrinol Metab* 62:305–313
 90. Andersen CY 1993 Characteristics of human follicular fluid asso-

- ciated with successful conception after *in vitro* fertilization. *J Clin Endocrinol Metab* 77:1227-1234
91. Aedo AR, Pedersen PH, Pedersen SC, Diczfalusy E 1980 Ovarian steroid secretion in normally menstruating women. I. The contribution of the developing follicle. *Acta Endocrinol (Copenh)* 95: 212-221
 92. Mason HD, Willis DS, Beard RW, Winston RML, Margara R, Franks S 1994 Estradiol production by granulosa cells of normal and polycystic ovaries: relationship to menstrual cycle history and concentrations of gonadotropins and sex steroids in follicular fluid. *J Clin Endocrinol Metab* 79:1355-1360
 93. Harlow CR, Shaw HJ, Hillier SG, Hodges JK 1988 Factors influencing FSH-induced steroidogenesis in marmoset granulosa cells: effects of androgens and stages of follicular development. *Endocrinology* 122:2780-2787
 94. McNatty KP, Moore-Smith D, Makris A, Osathanondh R, Ryan KJ 1979 The microenvironment of the human antral follicle: interrelationships among the steroid levels in antral fluid, the population of granulosa cells, and the status of the oocyte *in vivo* and *in vitro*. *J Clin Endocrinol Metab* 49:851-860
 95. Richards JS 1975 Estradiol receptor content in rat granulosa cells during follicular development: modification by estradiol and gonadotropins. *Endocrinology* 97:1174-1184
 96. Goldenberg RL, Reiter EO, Ross GT 1973 Follicle response to exogenous gonadotropins: an estrogen-mediated phenomenon. *Fertil Steril* 24:121-125
 97. Dorrington JH, Moon YS, Armstrong DT 1975 Estradiol-17beta biosynthesis in cultured granulosa cells from hypophysectomized immature rats; stimulation by follicle-stimulating hormone. *Endocrinology* 97:1328-1331
 98. Adashi EY, Hsueh AJ 1982 Estrogens augment the stimulation of ovarian aromatase activity by follicle-stimulating hormone in cultured rat granulosa cells. *J Biol Chem* 257:6077-6083
 99. Hsueh AJ, Adashi EY, Jones PB, Welsh THJ 1984 Hormonal regulation of the differentiation of cultured ovarian granulosa cells. *Endocr Rev* 5:76-127
 100. Hillier SG, Wickings EJ, Saunders PT, Dixson AF, Shimasaki S, Swanston IA, Reichert LEJ, McNeilly AS 1989 Control of inhibin production by primate granulosa cells. *J Endocrinol* 123:65-73
 101. Louvet JP, Vaitukaitis JL 1976 Induction of follicle-stimulating hormone receptors in rat ovaries by estrogen priming. *Endocrinology* 99:758-763
 102. Erickson GF, Wang C, Hsueh AJ 1979 FSH induction of functional LH receptors in granulosa cells cultured in a chemically defined medium. *Nature* 279:336-338
 103. Kessel B, Liu YX, Jia XC, Hsueh AJ 1985 Autocrine role of estrogens in the augmentation of luteinizing hormone receptor formation in cultured rat granulosa cells. *Biol Reprod* 32:1038-1050
 104. Reiter EO, Goldenberg RL, Vaitukaitis JL, Ross GT 1972 Evidence for a role of estrogen in the ovarian augmentation reaction. *Endocrinology* 91:1518-1522
 105. Franks S 1989 Polycystic ovary syndrome: a changing perspective. *Clin Endocrinol (Oxf)* 31:87-120
 106. Araki S, Chikazawa K, Sekiguchi I, Yamauchi H, Motoyama M, Tamada T 1987 Arrest of follicular development in a patient with 17 α -hydroxylase deficiency: folliculogenesis in association with a lack of estrogen synthesis in the ovaries. *Fertil Steril* 47:169-172
 107. Rabinovici J, Blankstein J, Goldman B, Rudak E, Dor Y, Pariente C, Geier A, Lunenfeld B, Mashiach S 1989 *In vitro* fertilization and primary embryonic cleavage are possible in 17 alpha-hydroxylase deficiency despite extremely low intrafollicular 17 beta-estradiol. *J Clin Endocrinol Metab* 68:693-697
 108. Pariente C, Rabinovici J, Lunenfeld B, Rudak E, Dor J, Mashiach S, Levrant D, Blankstein J, Geier A 1990 Steroid secretion by granulosa cells isolated from a woman with 17 α -hydroxylase deficiency. *J Clin Endocrinol Metab* 71:984-987
 109. Pellicer A, Miro F, Sampaio M, Gomez E, Bonilla-Musoles FM 1991 *In vitro* fertilization as a diagnostic and therapeutic tool in a patient with partial 17,20-desmolase deficiency. *Fertil Steril* 55: 970-975
 110. Conte FA, Grumbach MM, Ito Y, Fisher CR, Simpson ER 1994 A syndrome of female pseudohermaphroditism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom). *J Clin Endocrinol Metab* 78:1287-1292
 111. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K 1995 Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. *J Clin Endocrinol Metab* 80:3689-3698
 112. Zelinski-Wooten MB, Hess DL, Baughman WL, Molskness TA, Wolf DP, Stouffer RL 1993 Administration of an aromatase inhibitor during the late follicular phase of gonadotropin-treated cycles in rhesus monkeys: effects on follicle development, oocyte maturation, and subsequent luteal function. *J Clin Endocrinol Metab* 76:988-995
 113. Keene JL, Matzuk MM, Otani T, Fauser BC, Galway AB, Hsueh AJ, Boime I 1989 Expression of biologically active human follicle-tropin in Chinese hamster ovary cells. *J Biol Chem* 264:4769-4775
 114. Mannaerts B, De Leeuw R, Geelen J, Van Ravenstein A, Van Wezenbeek P, Schuur A, Kloosterboer H 1991 Comparative *in vitro* and *in vivo* studies on the biological characteristics of recombinant human FSH. *Endocrinology* 129:2623-2630
 115. Fauser BCJM 1997 Follicular development and oocyte maturation in hypogonadotropic women employing recombinant FSH. The role of oestrogens. *Hum Reprod*, in press
 116. Couzinet B, Lestrat N, Brailly S, Forest M, Schaison G 1988 Stimulation of ovarian follicular maturation with pure follicle-stimulating hormone in women with gonadotropin deficiency. *J Clin Endocrinol Metab* 66:552-556
 117. Remorgida V, Venturini PL, Anserini P, Lanera P, De Cecco L 1989 Administration of pure follicle-stimulating hormone during gonadotropin-releasing hormone agonist therapy in patients with clomiphene-resistant polycystic ovarian disease: hormonal evaluations and clinical perspectives. *Am J Obstet Gynecol* 160:108-113
 118. Latronico AC, Anasti J, Arnholt IJ, Rapaport R, Mendonca BB, Bloise W, Castro M, Tsigos C, Chrousos GP 1996 Testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene. *N Engl J Med* 334:507-512
 119. Toledo SP, Brunner HG, Kraaij R, Dahia PM, Hayashida CY, Kremer H, Themmen AP 1996 An inactivating mutation of the LH receptor causes amenorrhea in a 46 XX female. *J Clin Endocrinol Metab*, 81:3850-3854
 120. Karnitis VJ, Townson DH, Friedman CI, Danforth DR 1994 Recombinant human follicle-stimulating hormone stimulates multiple follicular growth, but minimal estrogen production in gonadotropin-releasing hormone antagonist-treated monkeys: examining the role of luteinizing hormone in follicular development and steroidogenesis. *J Clin Endocrinol Metab* 79:91-97
 121. Zelinski-Wooten MB, Hutchison JS, Hess DL, Wolf DP, Stouffer RL 1995 Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotropin-releasing hormone antagonist-treated monkeys. *Hum Reprod* 10:1658-1666
 122. Hild-Petito S, Stouffer RL, Brenner RM 1988 Immunocytochemical localization of estradiol and progesterone receptors in the monkey ovary throughout the menstrual cycle. *Endocrinology* 123: 2896-2905
 123. Hild-Petito S, West NB, Brenner RM, Stouffer RL 1991 Localization of androgen receptor in the follicle and corpus luteum of the primate ovary during the menstrual cycle. *Biol Reprod* 44:561-568
 124. Suzuki T, Sasano H, Kimura N, Tamura M, Fukaya T, Yajima A, Nagura H 1994 Immunohistochemical distribution of progesterone, androgen and oestrogen receptors in the human ovary during the menstrual cycle: relationship to expression of steroidogenic enzymes. *Hum Reprod* 9:1589-1595
 125. Hurst BS, Zilberstein M, Chou JY, Litman B, Stephens J, Leslie KK 1995 Estrogen receptors are present in human granulosa cells. *J Clin Endocrinol Metab* 80:229-232
 126. Olsson JH, Granberg S 1990 Effect of clomiphene isomers on oestradiol synthesis in cultured human granulosa cells. *Hum Reprod* 5:928-932
 127. Koering MJ, Danforth DR, Hodgen GD 1991 Early folliculogenesis in primate ovaries: testing the role of estrogen. *Biol Reprod* 45:890-897
 128. Hutz RJ, Gold DA, Dierschke DJ 1987 Diminished steroidogenic

- response of hamster granulosa cells to estrogen *in vitro*. Cell Tissue Res 248:531–534
129. **Fauser BCJM** 1994 Observations in favour of normal early follicle development and disturbed follicle selection in PCOS. Gynecol Endocrinol 8:75–82
 130. **Dekel N, Galiani D, Beers WH** 1983 Induction of maturation in follicle-enclosed oocytes: specific response to gonadotropins at different stages of follicular development. Biol Reprod 19:113–117
 131. **Danforth DR** 1995 Endocrine and paracrine control of oocyte development. Am J Obstet Gynecol 172:747–752
 132. **Tesarik J, Mendoza C** 1995 Nongenomic effects of 17 beta-estradiol on maturing human oocytes: relationship to oocyte developmental potential. J Clin Endocrinol Metab 80:1438–1443
 133. **DiZerega GS, Hodgen GD** 1981 Folliculogenesis in the primate ovarian cycle. Endocr Rev 2:27–49
 134. **Hodgen GD** 1982 The dominant ovarian follicle. Fertil Steril 38:281–300
 135. **Goodman AL, Hodgen GD** 1983 The ovarian triad of the primate menstrual cycle. Recent Prog Horm Res 39:1–73
 136. **Zeleznik AJ, Hillier SG** 1984 The role of gonadotropins in the selection of the preovulatory follicle. Clin Obstet Gynecol 27:927–940
 137. **Zeleznik AJ** 1993 Dynamics of human follicle growth: a physiologic perspective. In: Adashi EY, Leung PCK (eds) The Ovary. Raven Press, New York, pp 41–56
 138. **Goodman AL, Nixon WE, Johnson DK, Hodgen GD** 1977 Regulation of folliculogenesis in the cycling rhesus monkey: selection of the dominant follicle. Endocrinology 100:155–161
 139. **Zeleznik AJ, Resko JA** 1980 Progesterone does not inhibit gonadotropin-induced follicular maturation in the female rhesus monkey (*Macaca mulatta*). Endocrinology 106:1820–1826
 140. **DiZerega GS, Nixon WE, Hodgen GD** 1980 Intercycle serum FSH elevations: significance in recruitment and selection of the dominant follicle and assessment of corpus luteum normalcy. J Clin Endocrinol Metab 50:1046–1048
 141. **DiZerega GS, Marut EL, Turner CK, Hodgen GD** 1980 Asymmetrical ovarian function during recruitment and selection of the dominant follicle in the menstrual cycle of the rhesus monkey. J Clin Endocrinol Metab 51:698–701
 142. **DiZerega GS, Lynch A, Hodgen GD** 1981 Initiation of asymmetrical ovarian estradiol secretion in the primate ovarian cycle after luteectomy. Endocrinology 108:1233–1236
 143. **Zeleznik AJ, Kubik CJ** 1986 Ovarian response in macaques to pulsatile infusion of FSH and LH: increased sensitivity of the maturing follicle to FSH. Endocrinology 119:2025–2032
 144. **Zeleznik AJ** 1981 Premature elevation of systemic estradiol reduces serum levels of FSH and lengthens the follicular phase of the menstrual cycle in rhesus monkeys. Endocrinology 109:352–355
 145. **Zeleznik AJ, Hutchison JS, Schuler HM** 1985 Interference with the gonadotropin-suppressing actions of estradiol in macaques overrides the selection of a single preovulatory follicle. Endocrinology 117:991–999
 146. **Zeleznik AJ, Hutchison JS, Schuler HM** 1987 Passive immunization with anti-oestradiol antibodies during the luteal phase of the menstrual cycle potentiates the perimenopausal rise in serum gonadotrophin concentrations and stimulates follicle growth in the cynomolgus monkey. J Reprod Fertil 80:403–410
 147. **DiZerega GS, Hodgen GD** 1980 Cessation of folliculogenesis during the primate luteal phase. J Clin Endocrinol Metab 51:158–160
 148. **le Nestour E, Marraoui J, Lahlou N, Roger M, de Ziegler D, Bouchard P** 1993 Role of estradiol in the rise in follicle-stimulating hormone levels during the luteal-follicular transition. J Clin Endocrinol Metab 77:439–442
 149. **Roseff SJ, Bangah ML, Kettel LM, Vale W, Rivier J, Burger HG, Yen SS** 1989 Dynamic changes in circulating inhibin levels during the luteal-follicular transition of the human menstrual cycle. J Clin Endocrinol Metab 69:1033–1039
 150. **Hall JE, Schoenfeld DA, Martin KA, Crowley WF** 1992 Hypothalamic gonadotropin-releasing hormone secretion and follicle-stimulating hormone dynamics during the luteal-follicular transition. J Clin Endocrinol Metab 74:600–607
 151. **Brown JB** 1978 Pituitary control of ovarian function: concepts derived from gonadotrophin therapy. Aust N Z J Obstet Gynaecol 18:47–54
 152. **Van Weissenbruch MM, Schoemaker HC, Drexhage HA, Schoemaker J** 1993 Pharmacodynamics of human menopausal gonadotrophin (HMG) and follicle-stimulating hormone (FSH). The importance of the FSH concentration in initiating follicular growth in polycystic ovary-like disease. Hum Reprod 8:813–821
 153. **van der Meer M, Hompes PGA, Scheele F, Schoute E, Veersema S, Schoemaker J** 1994 Follicle stimulating hormone (FSH) dynamics of low dose step-up ovulation induction with FSH in patients with polycystic ovary syndrome. Hum Reprod 9:1612–1617
 154. **McNatty KP, Hillier SG, van den Boogaard AM, Trimbos-Kemper TC, Reichert LEJ, Van Hall EV** 1983 Follicular development during the luteal phase of the human menstrual cycle. J Clin Endocrinol Metab 56:1022–1031
 155. **Gougeon A, Lefevre B** 1983 Evolution of the diameters of the largest healthy and atretic follicles during the human menstrual cycle. J Reprod Fertil 69:497–502
 156. **Gougeon A, Testart J** 1990 Influence of human menopausal gonadotropin on the recruitment of human ovarian follicles. Fertil Steril 54:848–852
 157. **Nilsson L, Wikland M, Hamberger L** 1982 Recruitment of an ovulatory follicle in the human following follicle-ectomy and luteectomy. Fertil Steril 37:30–34
 158. **Araki S, Chikazawa K, Akabori A, Ijima K, Tamada T** 1983 Hormonal profile after removal of the dominant follicle and corpus luteum in women. Endocrinol Jpn 30:55–70
 159. **Baird DT, Backstrom T, McNeilly AS, Smith SK, Wathen CG** 1984 Effect of enucleation of the corpus luteum at different stages of the luteal phase of the human menstrual cycle on subsequent follicular development. J Reprod Fertil 70:615–624
 160. **Hall JE, Bhatta N, Adams JM, Rivier JE, Vale WW, Crowley Jr WF** 1991 Variable tolerance of the developing follicle and corpus luteum to gonadotropin-releasing hormone antagonist-induced gonadotropin withdrawal in the human. J Clin Endocrinol Metab 72:993–1000
 161. **Nelson LR, Fujimoto VY, Jaffe RB, Monroe SE** 1995 Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix). Fertil Steril 63:963–969
 162. **Hillier SG** 1985 Sex steroid metabolism and follicular development in the ovary. Oxf Rev Reprod Biol 7:168–222
 163. **van Santbrink EJP, van Dessel HJHM, Hop WC, De Jong FH, Fauser BCJM** 1995 Decremental follicle-stimulating hormone and dominant follicle development during the normal menstrual cycle. Fertil Steril 64:37–43
 164. **Hillier SG** 1994 Hormonal control of folliculogenesis and luteinization. In: Findlay JK (ed) Molecular Biology of the Female Reproductive Tract. Academic Press, San Diego, CA, pp 1–37
 165. **Yong EL, Baird DT, Yates R, Reichert Jr LE, Hillier SG** 1992 Hormonal regulation of the growth and steroidogenic function of human granulosa cells. J Clin Endocrinol Metab 74:842–849
 166. **Zeleznik AJ, Schuler HM, Reichert Jr LE** 1981 Gonadotropin-binding sites in the rhesus monkey ovary: Role of the vasculature in the selective distribution of human chorionic gonadotropin to the preovulatory follicle. Endocrinology 109:356–362
 167. **Kettel LM, Roseff SJ, Chiu TC, Bangah ML, Vale W, Rivier J, Burger HG, Yen SS** 1991 Follicular arrest during the midfollicular phase of the menstrual cycle: a gonadotropin-releasing hormone antagonist imposed follicular-follicular transition. J Clin Endocrinol Metab 73:644–649
 168. **Baird DT** 1987 A model for follicular selection and ovulation: lessons from super ovulation. J Steroid Biochem 27:15–23
 169. **Fauser BC, Donderwinkel P, Schoot DC** 1993 The step-down principle in gonadotrophin treatment and the role of GnRH analogues. Baillieres Clin Obstet Gynaecol 7:309–330
 170. **Fauser BCJM** 1994 Step down FSH regimens in PCOS. In: Filicori M, Flamigni C (eds) Ovulation Induction: Basic Science and Clinical Advances. Excerpta Medica International Congress Series, 1064. Elsevier, Amsterdam, The Netherlands, pp 153–162
 171. **Lolis DE, Tsolas O, Messinis IE** 1995 The follicle-stimulating hormone threshold level for follicle maturation in superovulated cycles. Fertil Steril 63:1272–1277

172. **Ben Rafael Z, Strauss III JF, Mastroianni LJ, Flickinger GL** 1986 Differences in ovarian stimulation in human menopausal gonadotropin treated woman may be related to follicle-stimulating hormone accumulation. *Fertil Steril* 46:586-592
173. **Schoot DC, Hop WCJ, De Jong FH, van Dessel TJHM, Fauser BCJM** 1995 Initial estradiol response predicts outcome of exogenous gonadotropins using a step-down dose regimen for induction of ovulation in polycystic ovary syndrome. *Fertil Steril* 64:1081-1087
174. **Baird DT** 1990 The selection of the follicle of the month. In: Evers JLH, Heineman MJ (eds) *From Ovulation to Implantation*. Excerpta Medica, Amsterdam, pp 3-19
175. **Groome NP, Illingworth PJ, O'Brien M, Pai R, Rodger FE, Mather JP, McNielly AS** 1996 Measurement of dimeric inhibin B throughout the human menstrual cycle. *J Clin Endocrinol Metab* 81:1401-1405
176. **Klein NA, Illingworth PJ, Groome NP, McNielly AS, Battaglia DE, Soules MR** 1996 Decreased inhibin B secretion is associated with the monotrophic FSH rise in older, ovulatory women: a study of serum and follicular fluid levels of dimeric inhibin A and B in spontaneous menstrual cycles. *J Clin Endocrinol Metab* 81:2742-2745
177. **Hackeloer BJ, Nitschke S, Daume E, Sturm G, Buchholz R** 1977 Ultrasonics of ovarian changes under gonadotrophine stimulation. *Geburtshilfe Frauenheilkd* 37:185-190
178. **Ylostalo P, Ronnberg L, Jouppila P** 1979 Measurement of the ovarian follicle by ultrasound in ovulation induction. *Fertil Steril* 31:651-655
179. **Hackeloer BJ, Fleming R, Robinson HP, Adam AH, Coutts JRT** 1979 Correlation of ultrasonic and endocrinologic assessment of human follicular development. *Am J Obstet Gynecol* 135:122-128
180. **Robertson RD, Picker RH, Wilson PC, Saunders DM** 1979 Assessment of ovulation by ultrasound and plasma estradiol determinations. *Obstet Gynecol* 54:686-691
181. **Queenan JT, O'Brien GD, Bains LM, Simpson J, Collins WP, Campbell S** 1980 Ultrasound scanning of ovaries to detect ovulation in women. *Fertil Steril* 34:99-105
182. **O'Herlihy C, De Crespigny LC, Lopata A, Johnston I, Hoult J, Robinson H** 1980 Preovulatory follicular size: a comparison of ultrasound and laparoscopic measurements. *Fertil Steril* 34:24-26
183. **Renaud RL, Macler J, Dervain I, Ehret MC, Aron C, Plas-Roser S, Spira A, Pollack H** 1980 Echographic study of follicular maturation and ovulation during the normal menstrual cycle. *Fertil Steril* 33:272-276
184. **Smith DH, Picker RH, Sinosich M, Saunders DM** 1980 Assessment of ovulation by ultrasound and estradiol levels during spontaneous and induced cycles. *Fertil Steril* 33:387-390
185. **Sano Y, Suzuki K, Arai K, Okinaga S, Tamaoki BI** 1981 Changes in enzyme activities related to steroidogenesis in human ovaries during the menstrual cycle. *J Clin Endocrinol Metab* 52:994-1001
186. **Wetzels LC, Hoogland HJ** 1982 Relation between ultrasonographic evidence of ovulation and hormonal parameters: luteinizing hormone surge and initial progesterone rise. *Fertil Steril* 37:336-341
187. **Bryce RL, Shuter B, Sinosich MJ, Stiel JN, Picker RH, Saunders DM** 1982 The value of ultrasound, gonadotropin, and estradiol measurements for precise ovulation prediction. *Fertil Steril* 37:42-45
188. **Hackeloer BJ, Sallam HN** 1983 Ultrasound scanning of ovarian follicles. *Clin Obstet Gynecol* 10:603-620
189. **Geisthovel F, Skubsch U, Zabel G, Schillinger H, Breckwoldt M** 1983 Ultrasonographic and endocrinological studies of ovarian function. *Ultrasound Med Biol [Suppl]* 2:603-608
190. **Leerentveld RA, van Gent I, van der Stoep M, Alberda BT, Wladimiroff JW** 1984 Comparison of Graafian follicle dimensions as determined by static and real-time sector scanning. *Fertil Steril* 42:929-931
191. **Rossavik IK, Gibbons WE** 1985 Variability of ovarian follicular growth in natural menstrual cycles. *Fertil Steril* 44:195-199
192. **Zegers-Hochschild F, Gomez Lira C, Parada M, Altieri Lorenzini E** 1984 A comparative study of the follicular growth profile in conception and nonconception cycles. *Fertil Steril* 41:244-247
193. **Leader A, Wiseman D, Taylor PJ** 1985 The prediction of ovulation: a comparison of the basal body temperature graph, cervical mucus score, and real-time pelvic ultrasonography. *Fertil Steril* 43:385-388
194. **Hull ME, Moghissi KS, Magyar DM, Hayes MF, Zador I, Olson JM** 1986 Correlation of serum estradiol levels and ultrasound monitoring to assess follicular maturation. *Fertil Steril* 46:42-45
195. **Nitschke-Dabelstein S** 1986 Monitoring of follicular development using ultrasonography. In: Insler V, Lunenfeld B (eds) *Infertility: Male and Female*. Churchill Livingstone, Edinburgh, U.K., pp 101-126
196. **Ritchie WG** 1986 Sonographic evaluation of normal and induced ovulation. *Radiology* 161:1-10
197. **Vermesh M, Kletzky OA, Davajan V, Israel R** 1987 Monitoring techniques to predict and detect ovulation. *Fertil Steril* 47:259-264
198. **Doody MC, Gibbons WE, Buttram Jr VC** 1988 Linear regression analysis of ultrasound follicular growth series: evidence for an abnormality of follicular growth in endometriosis patients. *Fertil Steril* 49:47-51
199. **Mango D, Scirpa P, Spina MA, Battaglia F, Tartaglia E, Manna P, Ricci S, Iacona T** 1988 Ultrasonic and endocrinologic relationships in spontaneous and induced follicular phase. *J Endocrinol Invest* 11:7-13
200. **Forman RG, Robinson J, Yudkin P, Egan D, Reynolds K, Barlow DH** 1991 What is the true follicular diameter: an assessment of the reproducibility of transvaginal ultrasound monitoring in stimulated cycles. *Fertil Steril* 56:989-992
201. **DeCherney AH, Romero R, Polan ML** 1982 Ultrasound in reproductive endocrinology. *Fertil Steril* 37:323-333
202. **Yee B, Barnes RB, Vargyas JM, Marrs RP** 1987 Correlation of transabdominal and transvaginal ultrasound measurements of follicle size and number with laparoscopic findings for *in vitro* fertilization. *Fertil Steril* 47:828-832
203. **Coleman BG, Arger PH, Grumbach K** 1988 Transvaginal and transabdominal sonography: prospective comparison. *Radiology* 168:625-632
204. **Fauser BCJM, Pache TD, Schoot DC** 1993 Dynamics of human follicle development. In: Hsueh AJW, Schomberg DW (eds) *Ovarian Cell Interactions: Genes to Physiology*. Sero Symposia Series. Springer Verlag, New York, pp 134-147
205. **van Dessel HJHM, van Santbrink EJP, Fauser BCJM** 1996 *In vivo* regulation of human follicle development. In: Hillensjo T, Ahren K (eds) *Gonadal Function: Genetics to Physiology*. Sero Symposia Series. Christengraf, Rome, pp 97-112
206. **Pache TD, Wladimiroff JW, De Jong FH, Hop WC, Fauser BC** 1990 Growth patterns of nondominant ovarian follicles during the normal menstrual cycle. *Fertil Steril* 54:638-642
207. **Fauser BCJM** 1996 Interference with follicle-stimulating hormone regulation of human ovarian function. *Mol Hum Reprod* 2:327-334
208. **Chappel SC** 1995 Heterogeneity of follicle-stimulating hormone: control and physiological function. *Hum Reprod Update* 1:479-487
209. **Ulloa-Aguirre A, Midgley AR, Beitins IZ, Padmanabhan V** 1995 Follicle-stimulating isohormones: characterization and physiological relevance. *Endocr Rev* 16:765-787
210. **Padmanabhan V, Lang LL, Sonstein J, Kelch RP, Beitins IZ** 1988 Modulation of serum FSH bioactivity and isoform distribution by estrogenic steroids in normal women and in gonadal dysgenesis. *J Clin Endocrinol Metab* 67:465-473
211. **Wide L, Bakos O** 1993 More basic forms of both human follicle-stimulating hormone and luteinizing hormone in serum at mid-cycle compared with the follicular or luteal phase. *J Clin Endocrinol Metab* 76:885-889
212. **Zambrano E, Olivares A, Mendez JP, Guerrero L, Diaz-Cueto L, Veldhuis JD, Ulloa-Aguirre A** 1995 Dynamics of basal and gonadotropin-releasing hormone-releasable serum follicle-stimulating hormone charge isoform distribution throughout the human menstrual cycle. *J Clin Endocrinol Metab* 80:1647-1656
213. **Jia XC, Kessel B, Yen SS, Tucker EM, Hsueh AJ** 1986 Serum bioactive follicle-stimulating hormone during the human menstrual cycle and in hyper- and hypogonadotropic states: application of a sensitive granulosa cell aromatase bioassay. *J Clin Endocrinol Metab* 62:1243-1249
214. **Reddi K, Wickings EJ, McNeilly AS, Baird DT, Hillier SG** 1990 Circulating bioactive follicle stimulating hormone and immuno-

- reactive inhibin levels during the normal human menstrual cycle. *Clin Endocrinol (Oxf)* 33:547-557
215. **Sanzo MA, Reichert LE** 1982 Gonadotropin receptor binding regulators in serum. *J Biol Chem* 257:6033-6040
 216. **Lee DW, Grasso P, Dattatreymurty B, Deziel MR, Reichert Jr LE** 1993 Purification of a high molecular weight follicle-stimulating hormone receptor-binding inhibitor from human follicular fluid. *J Clin Endocrinol Metab* 77:163-168
 217. **Albanese C, Christin-Maitre S, Sluss P, Crowley WF, Jameson JL** 1994 Development of a bioassay for follicle-stimulating hormone using recombinant human FSH receptor and a cAMP responsive luciferase reporter gene. *Mol Cell Endocrinol* 101:211-219
 218. **Anasti JN, Flack MR, Froehlich J, Nelson LM** 1995 The use of human recombinant gonadotropin receptors to search for immunoglobulin G-mediated premature ovarian failure. *J Clin Endocrinol Metab* 80:824-828
 219. **Schipper I, Fauser BC, ten Hakken PM, Rommerts FF** 1996 Application of a CHO cell line transfected with the human FSH receptor for the measurement of FSH receptor activation inhibitors in serum. *J Endocrinol*, 150:505-514
 - 219a. **Schipper I, Rommerts FFG, ten Hacken PM, Fauser BCJM** Low levels of FSH receptor activation inhibitors in serum and follicular fluid from controls and anovulatory patients. *J Clin Endocrinol Metab*, in press
 220. **Hsueh AJ, Jones PB, Adashi EY, Wang C, Zhuang LZ, Welsh THJ** 1983 Intraovarian mechanisms in the hormonal control of granulosa cell differentiation in rats. *J Reprod Fertil* 69:325-342
 221. **Hsueh AJ, Bicsak TA, Jia XC, Dahl KD, Fauser BC, Galway AB, Czekala N, Pavlou SN, Papkoff H, Keene J** 1989 Granulosa cells as hormone targets: the role of biologically active follicle-stimulating hormone in reproduction. *Recent Prog Horm Res* 45:209-273
 222. **Tonetta SA, DiZerega GS** 1989 Intraovarian regulation of follicular maturation. *Endocr Rev* 10:205-229
 223. **Adashi EY** 1991 The ovarian life cycle. In: Yen SSC, Jaffe RB (eds) *Reproductive Endocrinology*. Saunders, Philadelphia, pp 181-237
 224. **Hillensjo T, Bergh C, Carlsson B** 1992 Growth factors - normal follicular development. In: Sjoberg NO, Hamberger L, Janson PO, Owman C, Coelingh Bennink HJT (eds) *Local Regulation of Ovarian Function*. Parthenon Publishing, Carnforth, U.K., pp 89-96
 225. **Erickson GF** 1996 The ovarian connection. In: Adashi EY, Rock JA, Rosenwaks Z (eds) *Reproductive Endocrinology, Surgery, and Technology*. Lippincott-Raven, Philadelphia, pp 1141-1160
 226. **Mason HD, Margara R, Winston RM, Seppala M, Koistinen R, Franks S** 1993 Insulin-like growth factor-I (IGF-I) inhibits production of IGF-binding protein-1 while stimulating estradiol secretion in granulosa cells from normal and polycystic human ovaries. *J Clin Endocrinol Metab* 76:1275-1279
 227. **Findlay JK** 1994 Peripheral and local regulators of folliculogenesis. *Reprod Fertil Dev* 6:127-139
 228. **Miro F, Hillier SG** 1992 Relative effects of activin and inhibin on steroid hormone synthesis in primate granulosa cells. *J Clin Endocrinol Metab* 75:1556-1561
 229. **Steinkampf MP, Mendelson CR, Simpson ER** 1988 Effects of epidermal growth factor and insulin-like growth factor I on the level of mRNA encoding aromatase cytochrome P-450 of human ovarian granulosa cells. *Mol Cell Endocrinol* 59:93-99
 230. **Mason HD, Margara R, Winston RM, Beard RW, Reed MJ, Franks S** 1990 Inhibition of oestradiol production by epidermal growth factor in human granulosa cells of normal and polycystic ovaries. *Clin Endocrinol (Oxf)* 33:511-517
 231. **Hurst BS, Zacur HA, Schlaff WD, Damewood MD, Berkovitz GD** 1993 The effect of epidermal growth factor in human granulosa cells varies with follicle size. *J Endocrinol Invest* 16:143-145
 232. **Mason HD, Willis D, Holly JM, Cwyfan-Hughes SC, Seppala M, Franks S** 1992 Inhibitory effects of insulin-like growth factor-binding proteins on steroidogenesis by human granulosa cells in culture. *Mol Cell Endocrinol* 89:R1-R4
 233. **Franks S, Mason HD, Polson DW, Winston RM, Margara R, Reed MJ** 1988 Mechanism and management of ovulatory failure in women with polycystic ovary syndrome. *Hum Reprod* 3:531-534
 234. **Westergaard LG** 1992 Follicular atresia in the human ovary. In: Sjoberg NO, Hamberger L, Janson PO, Owman C, Coelingh-Bennink HJ (eds) *Local Regulation of Ovarian Function*. Parthenon Publishing, Casterton Hall, U.K., pp 55-64
 235. **Mason HD, Carr L, Leake R, Franks S** 1995 Production of transforming growth factor-alpha by normal and polycystic ovaries. *J Clin Endocrinol Metab* 80:2053-2056
 236. **Adashi EY** 1990 The potential relevance of cytokines to ovarian physiology: the emerging role of resident ovarian cells of the white blood cell series. *Endocr Rev* 11:454-464
 237. **Giudice LC** 1992 Insulin-like growth factors and ovarian follicular development. *Endocr Rev* 13:641-669
 238. **el-Roeiy A, Chen X, Roberts VJ, LeRoith D, Roberts Jr CT, Yen SSC** 1993 Expression of insulin-like growth factor-I (IGF-I) and IGF-II and the IGF-I, IGF-II, and insulin receptor genes and localization of the gene products in the human ovary. *J Clin Endocrinol Metab* 77:1411-1418
 239. **el-Roeiy A, Chen X, Roberts VJ, Shimasaki S, Ling N, LeRoith D, Roberts Jr CT, Yen SSC** 1994 Expression of the genes encoding the insulin-like growth factors (IGF-I and II), the IGF and insulin receptors, and IGF-binding proteins-1-6 and the localization of their gene products in normal and polycystic ovary syndrome ovaries. *J Clin Endocrinol Metab* 78:1488-1496
 240. **Ling N, Ui M, Shimonaka M, Shimasaki S, Bicsak TA** 1990 An IGF-binding protein in ovarian follicular fluid blocks FSH-stimulated steroid production by ovarian granulosa cells. In: Yen SSC, Vale WW (eds) *Neuroendocrine Regulation of Reproduction*. Serono Symposia Series. Norwell, pp 207-215
 241. **van Dessel HJHM, Chandrasekher YA, Yap SO, Lee PP, Hintz RL, Faessen GH, Braat DD, Fauser BC, Giudice LC** 1996 Serum and ovarian follicle fluid levels of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 and -3 during the normal menstrual cycle support an auto/paracrine role for the intraovarian IGF system. *J Clin Endocrinol Metab* 81:1224-1231
 242. **Chandrasekher YA, van Dessel HJHM, Fauser BCJM, Giudice LC** 1995 Estrogen- but not androgen dominant human ovarian follicular fluid contains an insulin-like growth factor binding protein-4 protease. *J Clin Endocrinol Metab* 80:2734-2739
 243. **Dor J, Ben-Shlomo I, Lunenfeld B, Pariente C, Levrin D, Karasik A, Seppala M, Mashiach S** 1992 Insulin-like growth factor-I (IGF-I) may not be essential for ovarian follicular development: Evidence from IGF-I deficiency. *J Clin Endocrinol Metab* 74:539-542
 244. **Schwartz M, Jewelewicz R** 1981 The use of gonadotropins for induction of ovulation. *Fertil Steril* 35:3-12
 245. **Lunenfeld B, Mashiach S, Blankstein J** 1985 Induction of ovulation with gonadotrophins. In: Shearman RP (ed) *Clinical Reproductive Endocrinology*. Churchill Livingstone, Edinburgh, pp 523-533
 246. **Brown JB** 1986 Gonadotropins. In: Insler V, Lunenfeld B (eds) *Infertility: Male and Female*. Churchill Livingstone, Edinburgh, pp 359-396
 247. **Insler V** 1988 Gonadotropin therapy: new trends and insights. *Int J Fertil* 33:85-97
 248. **Kelly AC, Jewelewicz R** 1990 Alternate regimens for ovulation induction in polycystic ovarian disease. *Fertil Steril* 54:195-202
 249. **Fauser BCJM** 1993 Clinical use of gonadotropins in women. In: Bouchard P, Caraty A, Coelingh Bennink HJT, Pavlou SN (eds) *GnRH, GnRH Analogs, Gonadotropins, and Gonadal Peptides*. Parthenon Publishing, London, U.K., pp 467-479
 250. **Franks S, Gilling-Smith C** 1994 Advances in induction of ovulation. *Curr Opin Obstet Gynecol* 6:136-140
 251. **Gemzell C, Diczfalusy E, Tillinger G** 1958 Clinical effect of human pituitary follicle-stimulating hormone. *J Clin Endocrinol Metab* 18:1333-1348
 252. **Taymor ML, Sturgis SH, Goldstein DP, Lieberman B** 1967 Induction of ovulation with human postmenopausal gonadotropin. *Fertil Steril* 18:181-190
 253. **Thompson CR, Hansen LM** 1970 Pergonal (menotropins): a summary of clinical experience in the induction of ovulation and pregnancy. *Fertil Steril* 21:844-853
 254. **Wilson EA, Jawad MJ, Hayden TL** 1982 Rates of exponential increase of serum estradiol concentrations in normal and human menopausal gonadotropin-induced cycles. *Fertil Steril* 37:46-49
 255. **Marrs RP, Vargyas JM, March CM** 1983 Correlation of ultrasonic

- and endocrinologic measurements in human menopausal gonadotropin therapy. *Am J Obstet Gynecol* 145:417–421
256. **Messinis IE, Templeton AA** 1990 The importance of follicle-stimulating hormone increase for folliculogenesis. *Hum Reprod* 5:153–156
 257. **Schoot DC, Fauser BCJM** 1992 Monitoring of follicular development during induction of ovulation using exogenous gonadotrophins. *Exp Clin Endocrinol* 11:303–306
 258. **Schenker JG, Yarkoni S, Granat M** 1981 Multiple pregnancies following induction of ovulation. *Fertil Steril* 35:105–123
 259. **Golan A, Ron-El R, Herman A, Soffer Y, Weinraub Z, Caspi E** 1989 Ovarian hyperstimulation syndrome: an update review. *Obstet Gynecol Surv* 44:430–440
 260. **Shoham Z, Zosmer A, Inslar V** 1991 Early miscarriage and fetal malformations after induction of ovulation (by clomiphene citrate and/or human menotropins), *in vitro* fertilization, and gamete intrafallopian transfer. *Fertil Steril* 55:1–11
 261. **Kamran KS, Taymor ML, Berger MJ** 1973 Estrogen monitoring and the prevention of ovarian overstimulation during gonadotropin therapy. *Am J Obstet Gynecol* 115:972–977
 262. **Haning RVJ, Levin RM, Behrman HR, Kase NG, Speroff L** 1979 Plasma estradiol window and urinary estriol glucuronide determinations for monitoring menotropin induction of ovulation. *Obstet Gynecol* 54:442–447
 263. **Haning RV, Austin CW, Carlson IH, Kuzma DL, Shapiro SS, Zweibel WJ** 1983 Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins. *Fertil Steril* 40:31–36
 264. **Blankstein J, Shalev J, Saadon T, Kukia EE, Rabinovici J, Pariente C, Lunenfeld B, Serr DM, Mashiach S** 1987 Ovarian hyperstimulation syndrome: prediction by number and size of preovulatory ovarian follicles. *Fertil Steril* 47:597–602
 265. **Regan L, Owen EJ, Jacobs HS** 1990 Hypersecretion of luteinising hormone, infertility, and miscarriage. *Lancet* 336:1141–1144
 266. **Balen AH, Tan S-L, Jacobs HS** 1993 Hypersecretion of luteinising hormone: a significant cause of infertility and miscarriage. *Br J Obstet Gynaecol* 100:1082–1089
 267. **Navot D, Goldstein N, Mor-Josef S, Simon A, Relou A, Birkenfeld A** 1991 Multiple pregnancies: risk factors and prognostic variables during induction of ovulation with human menopausal gonadotrophins. *Hum Reprod* 6:1152–1155
 268. **Levene MI, Wild J, Steer P** 1992 Higher multiple births and the modern management of infertility in Britain. The British Association of Perinatal Medicine. *Br J Obstet Gynaecol* 99:607–613
 269. **Derom C, Derom R, Vlietinck R, Maes H, van den Berghe H** 1993 Iatrogenic multiple pregnancies in East Flanders, Belgium. *Fertil Steril* 60:493–496
 270. **Dickey RP, Olar TT** 1993 Hormone treatment for infertility. Restriction won't prevent multiple pregnancies. *Br Med J* 307:1281–1282
 271. **Tuppin P, Blondel B, Kaminski M** 1993 Trends in multiple deliveries and infertility treatments in France. *Br J Obstet Gynaecol* 100:383–385
 272. **Evans MI, Dommergues M, Wapner RJ, Lynch L, Dumez Y, Goldberg JD, Zador IE, Nicolaides KH, Johnson MP, Golbus MS, Boulot P, Berkowitz RL** 1993 Efficacy of transabdominal multifetal pregnancy reduction: collaborative experience among the world's largest centers. *Obstet Gynecol* 82:61–66
 273. **Check JH, Nowroozi K, Vetter B, Rankin A, Dietterich C, Schubert B** 1993 The effects of multiple gestation and selective reduction on fetal outcome. *J Perinat Med* 21:299–302
 274. **Callahan TL, Hall JE, Etner SL, Christiansen CL, Greene MF, Crowley Jr WF** 1994 The economic impact of multiple-gestation pregnancies and the contribution of assisted-reproduction techniques to their incidence. *N Engl J Med* 331:244–249
 275. **Oelsner G, Serr DM, Mashiach S, Blankstein J, Snyder M, Lunenfeld B** 1978 The study of induction of ovulation with menotropins: analysis of results of 1897 treatment cycles. *Fertil Steril* 30:538–544
 276. **Dor J, Itzkowicz DJ, Mashiach S, Lunenfeld B, Serr DM** 1980 Cumulative conception rates following gonadotropin therapy. *Am J Obstet Gynecol* 136:102–105
 277. **Healy DL, Kovacs GT, Pepperell RJ, Burger HG** 1980 A normal cumulative conception rate after human pituitary gonadotropin. *Fertil Steril* 34:341–345
 278. **Schwartz M, Jewelewicz R, Dyrenfurth I, Tropper P, Vande Wiele RL** 1980 The use of human menopausal and chorionic gonadotrophins for induction of ovulation. Sixteen years' experience at the Sloane Hospital for Women. *Am J Obstet Gynecol* 138:801–807
 279. **Wang CF, Gemzell C** 1980 The use of human gonadotrophins for the induction of ovulation in women with polycystic ovarian disease. *Fertil Steril* 33:479–486
 280. **Ginsburg J, Hardiman P** 1991 Ovulation induction with human menopausal gonadotrophins—a changing scene. *Gynecol Endocrinol* 5:57–78
 281. **Hull MG** 1991 Gonadotropin therapy in anovulatory infertility. In: Howles CM (ed) *Gonadotrophins, GnRH Analogues, and Growth Factors in Infertility: Future Perspectives*. Alden Press, Oxford, U.K., pp 56–61
 282. **Franks S** 1995 Polycystic ovary syndrome. *N Engl J Med* 333:853–861
 283. **Mannaerts B, Shoham Z, Schoot D, Bouchard P, Harlin J, Fauser BC, Jacobs H, Rombout F, Coelingh Bennink H** 1993 Single-dose pharmacokinetics and pharmacodynamics of recombinant human follicle-stimulating hormone (Org 32489) in gonadotropin-deficient volunteers. *Fertil Steril* 59:108–114
 284. **Hamilton-Fairley D, Kiddy D, Watson H, Paterson C, Franks S** 1992 Association of moderate obesity with a poor pregnancy outcome in women with polycystic ovary syndrome treated with low dose gonadotrophin. *Br J Obstet Gynaecol* 99:128–131
 285. **McClure N, McQuinn B, McDonald J, Kovacs GT, Healy DL, Burger HG** 1992 Body weight, body mass index, and age: predictors of menotropin dose and cycle outcome in polycystic ovarian syndrome? *Fertil Steril* 58:622–624
 286. **Rodgers M, Mitchell R, Peers N, Robertson WR** 1992 Human chorionic gonadotropin contributes to the bioactivity of pergonal. *Clin Endocrinol (Oxf)* 37:558–564
 287. **Stokman PG, De Leeuw R, vd Wijngaard HA, Kloosterboer HJ, Vemer HM, Sanders AL** 1993 Human chorionic gonadotropin in commercial human menopausal gonadotropin preparations. *Fertil Steril* 60:175–178
 288. **Giudice E, Crisci C, Eshkol A, Papoian R** 1994 Composition of commercial gonadotrophin preparations extracted from human post-menopausal urine: characterization of non-gonadotrophin proteins. *Hum Reprod* 9:2291–2299
 289. **Donderwinkel PF, Schoot DC, Coelingh Bennink HJ, Fauser BC** 1992 Pregnancy after induction of ovulation with recombinant human FSH in polycystic ovary syndrome. *Lancet* 340:983
 290. **Hornnes P, Giroud D, Howles C, Loumaye E** 1993 Recombinant human follicle-stimulating hormone treatment leads to normal follicular growth, estradiol secretion, and pregnancy in a World Health Organization group II anovulatory woman. *Fertil Steril* 60:724–726
 291. **van Dessel HJHM, Donderwinkel PFJ, Coelingh Bennink HJT, Fauser BCJM** 1994 First established pregnancy and birth after induction of ovulation with recombinant human follicle-stimulating hormone in polycystic ovary syndrome. *Hum Reprod* 9:55–56
 292. **Boime I, Keene J, Galway AB, Fares FM, Lapolt R, Hsueh AJW** 1992 Expression of recombinant human FSH, LH and CG in mammalian cells: a structure-function model for therapeutic drug design. *Semin Reprod Endocrinol* 10:45–50
 293. **Porchet HC, le Cotonnec JY, Neuteboom B, Canali S, Zanolto G** 1995 Pharmacokinetics of recombinant human luteinizing hormone after intravenous, intramuscular, and subcutaneous administration in monkeys and comparison with intravenous administration of pituitary human luteinizing hormone. *J Clin Endocrinol Metab* 80:667–673
 294. **Fares FA, Suganuma N, Nishimori K, LaPolt PS, Hsueh AJ, Boime I** 1992 Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. *Proc Natl Acad Sci USA* 89:4304–4308
 295. **Bishop LA, Robertson DM, Cahir N, Schofield PR** 1994 Specific roles for the asparagine-linked carbohydrate residues of recombinant human FSH in receptor binding and signal transduction. *Mol Endocrinol* 8:722–731
 296. **Sugahara T, Pixley MR, Minami S, Perlas E, Ben-Menahem D,**

- Hsueh AJ, Boime I 1995 Biosynthesis of a biologically active single peptide chain containing the human common alpha and chorionic gonadotropin beta subunits in tandem. *Proc Natl Acad Sci USA* 92:2041-2045
297. Flack MR, Bennet AP, Froehlich J, Anasti JN, Nisula BC 1994 Increased biological activity due to basic isoforms in recombinant human follicle-stimulating hormone produced in a human cell line. *J Clin Endocrinol Metab* 79:756-760
298. Garcea N, Campo S, Panetta V, Venneri M, Siccardi P, Dargenio R, De Tomasi F 1985 Induction of ovulation with purified urinary follicle-stimulating hormone in patients with polycystic ovarian syndrome. *Am J Obstet Gynecol* 151:635-640
299. Larsen T, Larsen JF, Schioler V, Bostofte E, Felding C 1990 Comparison of urinary human follicle-stimulating hormone and human menopausal gonadotropin for ovarian stimulation in polycystic ovarian syndrome. *Fertil Steril* 53:426-431
300. McFaul PB, Traub AI, Thompson W 1990 Treatment of clomiphene citrate-resistant polycystic ovarian syndrome with pure follicle-stimulating hormone or human menopausal gonadotropin. *Fertil Steril* 53:792-797
301. Sagle MA, Hamilton-Fairley D, Kiddy DS, Franks S 1991 A comparative, randomized study of low-dose human menopausal gonadotrophin and follicle-stimulating hormone in women with polycystic ovarian syndrome. *Fertil Steril* 55:56-60
302. Harlin J, Khan SA, Diczfalusy E 1986 Molecular composition of LH and FSH in commercial gonadotropin preparations. *Fertil Steril* 46:1055-1061
303. Cook AS, Webster BW, Terranova PF, Keel BA 1988 Variation in the biological and biochemical characteristics of HMG. *Fertil Steril* 49:704-712
304. Rodgers M, McLoughlin JD, Lambert A, Robertson WR, Mitchell R 1995 Variability in the immunoreactive and bioactive follicle stimulating hormone content of human urinary menopausal gonadotrophin preparations. *Hum Reprod* 10:1982-1986
305. Dobbs KE, Dumesic DA, Dumesic JA, Shapiro SS 1994 Differences in serum follicle-stimulating hormone uptake after intramuscular and subcutaneous human menopausal gonadotropin injection. *Fertil Steril* 62:978-983
306. Ellenbogen A, Rosenberg R, Shulman A, Libal Y, Anderman S, Jaschewatzky O, Ballas S 1996 A follicular scoring system for monitoring ovulation induction in polycystic ovary syndrome patients based solely on ultrasonographic estimation of follicular development. *Fertil Steril* 65:1175-1177
307. Haning RV, Austin CW, Kuzma D, Shapiro S, Zweibel WJ 1982 Ultrasound evaluation of estrogen monitoring for induction of ovulation with menotropins. *Fertil Steril* 37:627-632
308. Sallam HN, Marinho AO, Collins WP, Rodeck CH, Campbell S 1982 Monitoring gonadotrophin therapy by real-time ultrasonic scanning of ovarian follicles. *Br J Obstet Gynaecol* 89:155-159
309. Hardiman P, Thomas M, Osgood V, Vlassopoulou V, Ginsburg J 1990 Are estrogen assays essential for monitoring gonadotropin stimulant therapy? *Gynecol Endocrinol* 4:261-269
310. Evron S, Navot D, Laufer N, Diamant YZ 1983 Induction of ovulation with combined human gonadotropins and dexamethasone in women with polycystic ovarian disease. *Fertil Steril* 40:183-186
311. Dodson WC, Hughes CLJ, Yancy SE, Haney AF 1989 Clinical characteristics of ovulation induction with human menopausal gonadotropins with and without leuprolide acetate in polycystic ovary syndrome. *Fertil Steril* 52:915-918
312. Schoot DC, Pijlman B, Stijnen T, Fauser BC 1992 Effects of gonadotropin release single hormone agonist addition to gonadotropin induction of ovulation in polycystic ovary syndrome patients. *Eur J Obstet Gynecol Reprod Biol* 45:53-58
313. Homburg R, Eshel A, Abdalla HI, Jacobs HS 1988 Growth hormone facilitates ovulation induction by gonadotrophins. *Clin Endocrinol (Oxf)* 29:113-117
314. Davoren JB, Hsueh AJ 1986 Growth hormone increases ovarian levels of immunoreactive somatomedin C/insulin-like growth factor I *in vivo*. *Endocrinology* 118:888-890
315. Jia XC, Kalmijn J, Hsueh AJ 1986 Growth hormone enhances follicle-stimulating hormone-induced differentiation of cultured rat granulosa cells. *Endocrinology* 118:1401-1409
316. Homburg R, West C, Torresani T, Jacobs HS 1990 Cotreatment with human growth hormone and gonadotropins for induction of ovulation: a controlled clinical trial. *Fertil Steril* 53:254-260
317. Katz E, Ricciarelli E, Adashi EY 1993 The potential relevance of growth hormone to female reproductive physiology and pathophysiology. *Fertil Steril* 59:8-34
318. European, Australian Multicenter Study 1995 Cotreatment with growth hormone and gonadotropin for ovulation induction in hypogonadotropic patients: a prospective, randomized, placebo-controlled, dose-response study. *Fertil Steril* 64:917-923
319. Empeaire JC, Parneix I 1994 Triggering ovulation with nasal Nafarelin in hMG-treatment cycles. In: Empeaire JC (ed) *The Triggering of Ovulation in Stimulated Cycles: hCG or LH?* Parthenon Publishing, New York, pp 253-268
320. Wu CH 1977 Plasma hormones in human gonadotropin induced ovulation. *Obstet Gynecol* 49:308-313
321. Healy DL, Burger HG 1983 Serum follicle-stimulating hormone, luteinizing hormone, and prolactin during the induction of ovulation with exogenous gonadotropin. *J Clin Endocrinol Metab* 56:474-478
322. Mallya S, Abdulla UA, Davis JC 1993 Measurement of serum levels of exogenously administered FSH and LH during ovulation induction therapy. *Gynecol Endocrinol* 7:167-171
323. Seibel MM, Kamrava MM, McArdle C, Taymore ML 1984 Treatment of PCOD with chronic low-dose FSH: biochemical changes and ultrasound correlation. *Int J Fertil* 29:39-43
324. Buvat J, Buvat-Herbaut M, Marcolin G, Dehaene JL, Verbecq P, Renouard O 1989 Purified follicle-stimulating hormone in polycystic ovary syndrome: slow administration is safer and more effective. *Fertil Steril* 52:553-559
325. Hamilton-Fairley D, Kiddy D, Watson H, Sagle M, Franks S 1991 Low-dose gonadotrophin therapy for induction of ovulation in 100 women with polycystic ovary syndrome. *Hum Reprod* 6:1095-1099
326. Shoham Z, Patel A, Jacobs HS 1991 Polycystic ovarian syndrome: safety and effectiveness of stepwise and low-dose administration of purified follicle-stimulating hormone. *Fertil Steril* 55:1051-1056
327. Dale PO, Tanbo T, Haug E, Abyholm T 1992 Polycystic ovary syndrome: low-dose follicle stimulating hormone administration is a safe stimulation regimen even in previous hyper-responsive patients. *Hum Reprod* 7:1085-1089
328. Bregieiro LO, de Moura MD, Ferriani RA, Bailao LA, de Sa MF 1993 Ovulation induction with low doses of "pure" follicle stimulating hormone using a fixed protocol in patients with polycystic ovarian disease. *Int J Fertil Menopausal Studies* 38:152-159
329. Buckler HM, Critchley HO, Cantrill JA, Shalet SM, Anderson DC, Robertson WR 1993 Efficacy of low dose purified FSH in ovulation induction following pituitary desensitization in polycystic ovarian syndrome. *Clin Endocrinol (Oxf)* 38:209-217
330. Dale O, Tanbo T, Lunde O, Abyholm T 1993 Ovulation induction with low-dose follicle-stimulating hormone in women with the polycystic ovary syndrome. *Acta Obstet Gynecol Scand* 72:43-46
331. Herman A, Ron-El R, Golan A, Soffer Y, Bukovsky I, Caspi E 1993 Overstimulated cycles under low-dose gonadotrophins in patients with polycystic ovary syndrome: characterization and management. *Hum Reprod* 8:30-34
332. Balen AH, Braat DD, West C, Patel A, Jacobs HS 1994 Cumulative conception and life birth rates after the treatment of anovulatory infertility: safety and efficacy of ovulation induction in 200 patients. *Hum Reprod* 9:1563-1570
333. Strowitzki T, Seehaus D, Korell M, Hepp H 1994 Low-dose follicle stimulating hormone for ovulation induction in polycystic ovary syndrome. *J Reprod Med* 39:499-503
334. Homburg R, Levy T, Ben-Rafael Z 1995 A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome. *Fertil Steril* 63:729-733
335. Ben-Rafael Z, Levy T, Schoemaker J 1995 Pharmacokinetics of FSH: clinical significance. *Fertil Steril* 63:689-700
336. Mizunuma H, Takagi T, Honjyo S, Ibuki Y, Igarashi M 1990 Clinical pharmacodynamics of urinary follicle-stimulating hormone and its application for pharmacokinetic simulation program. *Fertil Steril* 53:440-445
337. White DM, Polson DW, Hamilton-Fairley D, Franks S, Evidence for negative feedback control of follicle-stimulating hormone dur-

- ing unifollicular ovulatory cycles induced by low-dose gonadotropin in polycystic ovarian syndrome. Program of the 58th Annual Meeting of the European Society of Human Reproduction, Hamburg, Germany, 1995 (Abstract 118)
338. **Abbasi R, Kenigsberg D, Danforth D, Falk RJ, Hodgen GD** 1987 Cumulative ovulation rate in human menopausal/human chorionic gonadotropin-treated monkeys: "step-up" vs. "step-down" dose regimens. *Fertil Steril* 47:1019-1024
 339. **Schoot DC, Pache TD, Hop WC, De Jong FH, Fauser BC** 1992 Growth patterns of ovarian follicles during induction of ovulation with decreasing doses of human menopausal gonadotropin following presumed selection in polycystic ovary syndrome. *Fertil Steril* 57:1117-1120
 340. **Schoot DC, Hop WC, Pache TD, De Jong FH, Fauser BC** 1993 Growth of the dominant follicle is similar to normal in patients with gonadotrophin-stimulated polycystic ovary syndrome exhibiting monofollicular development during a decremental dose regimen. *Acta Endocrinol (Copenh)* 129:126-129
 341. **van Dessel HJHM, Schoot BC, Schipper J, Dahl KD, Fauser BCJM** 1996 Circulating immunoreactive and bioactive serum follicle-stimulating hormone levels in normogonadotropic anovulatory infertile women and during gonadotropin induction of ovulation applying a decremental dose regimen. *Hum Reprod* 11:478-485
 342. **Mortola JF, Laughlin GA, Yen SS** 1992 A circadian rhythm of serum follicle-stimulating hormone in women. *J Clin Endocrinol Metab* 75:861-864
 343. **van Santbrink EJP, Donderwinkel PFJ, van Dessel HJHM, Fauser BCJM** 1995 Gonadotrophin induction of ovulation using a step down dose regimen: Single-center clinical experience in 82 patients. *Hum Reprod* 10:1048-1053
 344. **Glasier AF, Baird DT, Hillier SG** 1989 FSH and the control of follicular growth. *J Steroid Biochem* 32:167-170
 345. **Mizunuma H, Takagi T, Yamada K, Ibuki Y, Igarashi M** 1991 Ovulation induction by step down administration of purified FSH in patients with polycystic ovary syndrome. *Fertil Steril* 55:1195-1197
 346. **Steinkampf MP, Banks KS** 1993 Step-down vs. conventional FSH treatment in patients with WHO group II amenorrhea: results of a US multicenter clinical trial. *Proc Annu Meet Am Fertil Soc [Suppl]* :S21-S22 (Abstract 0-044)
 347. **Hugues JN, Cedrin-Durnerin I, Avril C, Herve F, Pecqueur L, Uzan M** 1996 Sequential step-up and step-down regimen for induction of ovulation in patients with polycystic ovary syndrome. *J Soc Gynecol Invest* 3:82A (Abstract 48)
 348. **Kuwahara A, Matsuzaki T, Kaji H, Irahara M, Aono T** 1995 Induction of single ovulation by sequential follicle-stimulating hormone and pulsatile gonadotropin-releasing hormone treatment. *Fertil Steril* 64:267-272
 349. **Mishell DR, Kletzky OA, Brenner PF, Roy S, Nicoloff J** 1977 The effect of contraceptive steroids on hypothalamic pituitary function. *Am J Obstet Gynecol* 138:60-74
 350. **Hemrika DJ, Slaats EH, Kennedy JC, de Vries Robles-Korsen TJ, Schoemaker J** 1993 Pulsatile luteinizing hormone patterns in long term oral contraceptive users. *J Clin Endocrinol Metab* 77:420-426
 351. **Preston SN** 1974 A report of the correlation between the pregnancy rates of low estrogen formulations and pill-taking habits of females studied. *J Reprod Med* 13:75-77
 352. **Wenzl R, Coelingh-Bennink HJ, vBeek A, Spona J, Huber J** 1993 Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17 β -estradiol. *Fertil Steril* 60:616-619
 353. **Henzl MR** 1993 Evolution of steroids and their contraceptive and therapeutic use. In: Shoupe D, Haseltine FP (eds) *Contraception*. Springer Verlag, New York, pp 1-16
 354. **Molloy BG, Coulson KA, Lee JM, Watters JK** 1985 "Missed pill" conception: fact or fiction? *Br Med J* 290:1474-1475
 355. **Guillebaud J** 1986 The forgotten pill— and the paramount importance of the pill-free week. *Br J Fam Plann* 12:35-43
 356. **Elstein M** 1994 Low dose contraceptive formulations: is further reduction in steroid dosage justified? *Adv Contracept* 10:1-4
 357. **Finlay IG, Scott MGB** 1986 Patterns of oral contraceptive pill taking in an inner city practice. *Br Med J* 293:601
 358. **Klitsch M** 1991 How well do women comply with oral contraceptive regimens? *Fam Plann Perspect* 23:134-138
 359. **Fraser IS, Jansen RP** 1983 Why do inadvertent pregnancies occur in oral contraceptive users? Effectiveness of oral contraceptive regimens and interfering factors. *Contraception* 27:531-551
 360. **Grady WR, Hayward MD, Yagi J** 1986 Contraceptive failure in the United States: estimates from the 1982 National Survey of Family Growth. *Fam Plann Perspect* 18:200-209
 361. **Trussell J, Kost K** 1987 Contraceptive failure in the United States: a critical review of the literature. *Stud Fam Plann* 18:237-283
 362. **Trussell J, Hatcher RA, Cates W, Hance Stewart F, Kost K** 1990 A guide to interpreting contraceptive efficacy studies. *Contracept Efficacy* 76:558-567
 363. **Savonius H, Pakarinen P, Sjoberg L, Kajanoja P** 1995 Reasons for pregnancy termination: negligence or failure of contraception? *Acta Obstet Gynecol Scand* 74:818-821
 364. **Ling WY, Johnston DW, Lea RH, Bent AE, Scott JZ, Toews MR** 1985 Serum gonadotropin and ovarian steroid levels in women during administration of a norethindrone-ethinylestradiol triphasic oral contraceptive. *Contraception* 32:367-375
 365. **Stickland J, Tolowinska IY, Anthony F, Dennis KJ** 1987 The suppression of ovarian function by the new oral contraceptive—Femodene. *Contraception* 35:447-456
 366. **Danforth DR, Hodgen GD** 1989 "Sunday start" multiphasic oral contraception: ovulation prevention and delayed follicular atresia in primates. *Contraception* 39:321-330
 367. **Killick SR, Eyong E, Elstein M** 1987 Ovarian follicular development in oral contraceptive cycles. *Fertil Steril* 48:409-413
 368. **Loudon N** 1977 Starting on the pill. *Br Med J* 2:521-522
 369. **van der Does J, Exalto N, Dieben T, Coelingh Bennink H** 1995 Ovarian activity suppression by two different low-dose triphasic oral contraceptives. *Contraception* 52:357-361
 370. **Murphy A, Cropp CS, Smith BS, Burkman RT, Zacur HA** 1990 Effect of low-dose oral contraceptive on gonadotropins, androgens, and sex hormone binding globulin in nonhirsute women. *Fertil Steril* 53:35-39
 371. **Spellacy WN, Kalra PS, Buhi WC, Birk SA** 1980 Pituitary and ovarian responsive ness to a graded gonadotropin releasing factor stimulation test in women using a low-estrogen or a regular type of oral contraceptive. *Am J Obstet Gynecol* 137:109-115
 372. **Haefeli M, Werner-Zodrow I, Huber PR** 1991 Clinical experience with Mercilon and Marvelon with particular reference to ovarian function. *Geburtshilfe Frauenheilkd* 51:34-38
 373. **Smith SK, Kirkman RJ, Arce BB, McNeilly AS, Loudon NB, Baird DT** 1986 The effect of deliberate omission of Trinordiol or Mirogynon on the hypothalamo-pituitary-ovarian axis. *Contraception* 34:513-522
 374. **Benagiano G, Primiero FM, Bastianelli C, Abbondante G, Grottanelli F, Tunnera G** 1990 Ovarian activity during oral contraception. *Adv Contracept* 6:245
 375. **Grimes DA, Godwin AJ, Rubin A, Smith JA, Lacarra M** 1994 Ovulation and follicular development associated with three low-dose oral contraceptives: a randomized controlled trial. *Obstet Gynecol* 83:29-34
 376. **Benagiano G** 1989 Comparison of 2 monophasic oral contraceptives: gestodene/ethinyl estradiol vs. desogestrel/ethinyl estradiol. *Int J Fertil* 34 [Suppl]:31-39
 377. **Fitzgerald C, Feichtinger W, Spona J, Elstein M, Ludicke F, Muller-Williams C** 1994 A comparison of the effects of two monophasic low dose oral contraceptives on the inhibition of ovulation. *Adv Contracept* 10:5-18
 378. **Broome M, Clayton J, Fotherby K** 1995 Enlarged follicles in women using oral contraceptives. *Contraception* 52:13-16
 379. **Landgren BM, Diczfalusy E** 1980 Hormonal effects of the 300 microgram norethisterone (NET) minipill. I. Daily steroid levels in 43 subjects during a pretreatment cycle and during the second month of NET administration. *Contraception* 21:87-113
 380. **Tayob Y, Adams J, Jacobs HS, Guillebaud J** 1985 Ultrasound demonstration of increased frequency of functional ovarian cysts in women using progestogen-only oral contraception. *Br J Obstet Gynaecol* 92:1003-1009
 381. **Alvarez F, Brache V, Tejada AS, Faundes A** 1986 Abnormal endocrine profile among women with confirmed or presumed ovulation during long-term Norplant use. *Contraception* 33:111-119

382. **Faundes A, Brache V, Tejada AS, Cochon L, Alvarez-Sanchez F** 1991 Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants. *Fertil Steril* 56:27-31
383. **Shoupe D, Horenstein J, Mishell DRJ, Lacarra M, Medearis A** 1991 Characteristics of ovarian follicular development in Norplant users. *Fertil Steril* 55:766-770
384. **Shaaban MM, Segal S, Salem HT, Ghaneimah SA, Khalifa EA, Ahmed AG** 1993 Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels. *Fertil Steril* 59:998-1002
385. **Brache V, Alvarez-Sanchez F, Faundes A, Tejada AS, Cochon L** 1990 Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants. *Contraception* 41:169-177
386. **Sivin I** 1994 Contraception with NORPLANT implants. *Hum Reprod* 9:1818-1826
387. **Voordouw BC, Euser R, Verdonk RE, Alberda BT, De Jong FH, Drogendijk AC, Fauser BC, Cohen M** 1992 Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. *J Clin Endocrinol Metab* 74:108-117
388. **Thomas K, Vankrieken L** 1990 Inhibition of ovulation by low-dose monophasic contraceptive containing gestodene. *Am J Obstet Gynecol* 163:1404-1410
389. **van der Spuy ZM, Sohnius U, Pienaar CA, Schall R** 1990 Gonadotropin and estradiol secretion during the week of placebo therapy in oral contraceptive pill users. *Contraception* 42:597-609
390. **Letterie GS, Chow GE** 1992 Effect of "missed" pills on oral contraceptive effective ness. *Obstet Gynecol* 79:979-982
391. **Dericks-Tan JS, Gudacker V, Taubert HD** 1992 Influence of oral contraceptives on integrated secretion of gonadotropins. *Contraception* 46:369-377
392. **Tayob Y, Robinson G, Adams J, Nye M, Whitelaw N, Shaw RW, Jacobs HS, Guillebaud J** 1990 Ultrasound appearance of the ovaries during the pill-free interval. *Br J Fam Plann* 16:94-96
393. **van Heusden AM, Coelingh-Bennink HJT, Fauser BCJM**, Comparison of ovarian function after the pill-free interval and following recFSH administration combined with suppression of the pituitary-ovarian axis. Annual Meeting of The Endocrine Society, Anaheim, CA, 1994, p 412 (Abstract 848)
394. **Wang E, Shi S, Cekan SZ, Landgren BM, Diczfalusy E** 1982 Hormonal consequences of "missing the pill". *Contraception* 26:545-566
395. **Hedon B, Cristol P, Plauchut A, Vallon AM, Desachamps F, Taillant ML, Mares P, Pizelle AM, Laffargue F, Viala JL** 1992 Ovarian consequences of the transient interruption of combined oral contraceptives. *Int J Fertil* 37:270-276
396. **Chowdhury V, Joshi UM, Gopalkrishna K, Betrabet S, Mehta S, Saxena BN** 1980 'Escape' ovulation in women due to the missing of low dose combination oral contraceptive pills. *Contraception* 22:241-247
397. **Talwar PP, Dingfelder JR, Ravenholt RT** 1977 Increased risk of breakthrough bleeding when one oral-contraceptive tablet is missed. *N Engl J Med* 296:987-988
398. **Morris SE, Groom GV, Cameron ED, Buckingham MS, Everitt JM, Elstein M** 1979 Studies on low dose oral contraceptives: plasma hormone changes in relation to deliberate pill ('Microgynon 30') omission. *Contraception* 20:61-69
399. **Landgren BM, Csemiczky G** 1991 The effect of follicular growth and luteal functi on of "missing the pill". A comparison between a monophasic and a triphasic combined oral contraceptive. *Contraception* 43:149-159
400. **van der Vange N** 1986 Seven Low Dose Oral Contraceptives and Their Influence on Metabolic Pathways and Ovarian Activity. Thesis, University of Utrecht. Optimax, Wijk bij Duurstede
401. **Hamilton CJ, Hoogland HJ** 1989 Longitudinal ultrasound study of the ovarian suppressive activity of a low-dose triphasic oral contraceptive during correct pill intake. *Am J Obstet Gynecol* 161:1159-1162
402. **Shaw G, Killick S, Elstein M** 1992 Assessment of ovarian activity in a gestodene containing triphasic oral contraceptive. *Br J Fam Plann* 18:76-78
403. **Young RL, Snabes MC, Frank ML, Reilly M** 1992 A randomized, double-blind, placebo-controlled comparison of the impact of low-dose and triphasic oral contraceptives on follicular development. *Am J Obstet Gynecol* 167:678-682
404. **Hoogland HJ, Skouby SO** 1993 Ultrasound evaluation of ovarian activity under oral contraceptives. *Contraception* 47:583-590
405. **Killick SR** 1989 Ovarian follicles during oral contraceptive cycles: their potential for ovulation. *Fertil Steril* 52:580-582
406. **Lanes SF, Birmann B, Walker AM, Singer S** 1992 Oral contraceptive type and functional ovarian cysts. *Am J Obstet Gynecol* 166:956-961
407. **Christie D** 1989 Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate. *Int J Fertil* 34:40-49
408. **Corson SL** 1994 Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate. *Am J Obstet Gynecol* 170 [Suppl]:1556-1561
409. **Hamerlynck JV, Vollebregt JA, Doornebos CM, Muntendam P** 1987 Postponement of withdrawal bleeding in women using low-dose combined oral contraceptives. *Contraception* 35:199-205
410. **de Voogd WS** 1991 Postponement of withdrawal bleeding with a monophasic oral contraceptive containing desogestrel and ethinylestradiol. *Contraception* 44:107-112
411. **Loudon NB, Foxwell M, Potts DM, Guild AL, Short RV** 1977 Acceptability of an oral contraceptive that reduces the frequency of menstruation: the tri-cycle pill regimen. *Br Med J* 2:487-490
412. **Hsueh AJ** 1995 Designer contraceptive pills. *Hum Reprod* 10:1997-2000